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While amyloid fibers made up of misfolded peptides or proteins are the hallmarks of over 
20 different amyloid diseases including Alzheimer’s Disease and Type II Diabetes, it is the elusive 
and transient oligomers that are the toxic player in disease. These oligomers impact toxicity in a 
variety of different avenues but are highly implicated in disrupting cellular membranes causing an 
imbalance in cell homeostasis leading to cell death. Understanding the steps involved in amyloid 
oligomer formation and membrane interactions is vital to developing therapeutics for these 
diseases. In these studies, the use of small molecules as a chemical biology tool to trap amyloid 
species in the presence and absence of cellular membrane mimetics and is demonstrated through 
a combination of NMR spectroscopy, fluorescence kinetics, transmission electron microscopy and 
circular dichroism, understand the structure and related cell toxicity. 
The effect of CurDAc, a water-soluble curcumin derivative, on three different 
amyloidogenic peptides: human-IAPP (hIAPP), amyloid-beta (Aβ) and human calcitonin (hCT) 
was evaluated for its inhibitory and disaggregation activity. CurDAc interaction with amyloid is 
structurally selective which is reflected in a strong interference with hIAPP aggregation, while 
showing weaker interactions with hCT and Aβ40 in comparison. Cell toxicity experiments 
demonstrated that CurDAc alone is non-toxic, however, remarkably both hIAPP monomers and 
fibers treated with CurDAc are more toxic than hIAPP monomers or fibers alone, suggesting that 
CurDAc stabilizes toxic species of hIAPP. Through the utilization of NMR spectroscopy, spectra 




are in a noticeably different chemical environment than the monomer. This study shows the 
potential of CurDAc to be used as a chemical probe to study hIAPP and suggests the mechanism 
of action is sequence specific. 
Amyloid-β aggregation at the cell-membrane of neuronal cells is implicated as a source of 
toxicity for Alzheimer’s disease. Small molecules have been studied for their ability to suppress 
amyloid aggregation and toxicity, but often the presence of membranes negate their activity. A 
high throughput screen of 1,800 small molecules was performed to search for membrane active 
inhibitors and 21 primary hits were discovered. Through the use of fluorescence-based assays, 
transmission electron microscopy, and dot blot assays the initial 21 primary hits were narrowed 
down to 5 lead compounds. NMR spectroscopy, circular dichroism, and size exclusion 
chromatography allowed for further confirmation of inhibition at the membrane interface as well 
as insights into the secondary structure and size of Amyloid-β, respectively. Lastly, dye leakage 
assays allowed for understanding as to how the addition of the 5 lead compounds affected 
Amyloid-β’s ability to permeate the lipid bilayer.  
These results provide insights into small molecules that stabilize small amyloid species in 
the absence and presence of membranes for the development of tool compounds for deeper 




Introduction to Amyloid Proteins and Their Interactions with Small Molecules and 
Membranes 
1.1 Overview of amyloids 
The term “amyloid” coming from the Latin word “amylum”, meaning starch, was first 
coined in 1838 as a description of amylaceous constituent in plants. In 1854, it was adopted by 
Rudolph Virchow to describe “starchy” deposits in a post mortem brain.1 While amyloid was 
named in the brain, physicians in the XVII century began to describe amyloid-like deposits in post 
mortem livers and bones. 2 Today, the term amyloid is used to describe proteins and peptides that 
can adopt highly uniform fibers which are self-templated and with beta-sheet structured unilateral 
characteristics. Currently, there are over 50 different known proteins or peptides in humans, 
bacteria, and yeast that are considered amyloids, (Table 1.1). A large portion of these amyloids are 
related to human disease, which can be divided into two main categories: neuropathic or non-
neuropathic, depending on the area of the body where they deposit.3 In some species, some amyloid 
proteins are considered to have a positive function, usually in bacteria or yeast, which impact the 
organism by contributing to their survival.4 In the case of amyloids related to human illnesses, a 
misfolding process negatively impacts the protein by altering its native state and function.5 It needs 
to be highlighted that for a portion of human diseases, the protein or peptide is intrinsically 
disordered and their switching mechanism to become amyloid fibers is unknown. Therefore, many 
scientific endeavors in a variety of disciplines have set out to understand their 
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structure, function, and disease-related states as well as develop treatments for diseases caused by 
amyloids. 
Amyloid fibers, either prepared in vitro or obtained from tissue samples, are filamentous 
structures composed of many monomeric units of the same protein in a beta-sheet structure that 
oriented unilaterally to the fiber axis (Figure 1.1 B). Individual monomeric beta-sheets are held 
together to their neighboring units via hydrogen bonding interactions. They are generally about 10 
Protein or Peptide Number of Residues Disease 
Amyloid-β 40/42 Alzheimer’s Disease 
α-Synuclein 140 Parkinson’s Disease 





352-441 Pick Disease 
Huntingtin Exon 1 (HttEx1) 103-187 Huntington Disease 
Immunoglobulin Light Chains 100 Amyloidosis 
Immunoglobulin Heavy Chains 190 Amyloidosis 
Serum Amyloid A protein (SAA) 45-104 AA Amyloidosis 
Transthyretin (TTR) 127 Senile Systemic Amyloidosis 
β2-microglobulin (β2-m) 99 Dialysis-Related Amyloidosis 
Hereditary Visceral Amyloidosis 
Apolipoprotein A/C 69-100 Apo A/C Amyloidosis 
Lysozyme (LYS) 130 Lysozyme Amyloidosis 
Islet Amyloid Polypeptide 
(IAPP) 
37 Type 2 Diabetes 
Calcitonin 32 Medullary Carcinoma 
Insulin 51 Injection Amyloidosis 
Protein or Peptide Number of Residues Species 
Curli variable depending on 
species 
E.coli, Salmonella 
Microcin E492 84 K. pneumoniae   
Chaplins 55-225 depending on 
isoform 
S. coelicolor 
Sup35NM 253 S. cerevisiae 
Table 1.1 List of commonly studied amyloid proteins. The length of the protein or peptide is 




nm in diameter but can be multiple microns in length. Typically, they are composed of two 
individual protofibers filaments that come together to form one final fiber held together by 
hydrogen bonding as well. However, there have been examples of mono-proto and tri-proto fibers 
too. Including their final fiber structure, there are many similarities that unify amyloidogenic 
proteins (Figure 1.1). These similarities include following a general aggregation mechanism going 
from a monomer, oligomer protofiber to fiber, binding histological dyes, depositing outside of 
cells, being hyper stable and resistance to breakdown or proteolysis, and containing a sequence of 
Figure 1.1. Unifying characteristics among amyloids. (A) The nucleated polymerization 
mechanism followed by amyloids from their disordered monomer structure to highly ordered beta 
sheet fibers, with a variety of structures and transitions throughout the process. (B) Final fiber 
structure is most commonly composted of two mirroring beta sheet fibers with individual 
monomers orienting perpendicularly to a unilateral fiber axis. (C) Cartoon representation of 
amyloid deposits occurring outside of neurons and in the extracellular space. Amyloid deposits 
occur outside of cells in nonneuropathic diseases as well. (D) Amyloid fibers exist at a low energy 
minimum making them hyper stable and highly resistant to disruption. The higher energy 
disordered monomer samples lower energy oligomers before making the transition to fibers. 
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hydrophobic and or aromatic residues that nucleate the self-assembly known as the amyloidogenic 
core.6  
 
1.2 Alzheimer’s disease and Amyloid-β 
Alzheimer’s disease (AD) is degenerative brain disease and the most common cause of 
dementia in the world. Unfortunately, despite many years of research, there is no known cure.7,8 
The hallmark of this disease is the formation of extracellular plaques in post-mortem brains. 
Currently in 2019, there are 5.8 million Americans suffering from the disease and this number is 
expected to triple by 2050.9 It is believed that the “amyloid cascade hypothesis”, which led to 
much research in many amyloid diseases, started with implicating Amyloid-β (Aβ) as the cause of 
AD.10,11 Aβ is the most abundant protein found in the plaques in the extracellular space of neurons, 
specifically the hippocampus, amygdala, and association neocortex. It is cleaved from the larger 
amyloid precursor protein (APP) in the extracellular membrane of neurons.12  The normal 
physiological role of both, APP and Aβ, is still unknown, however, it has been shown that they are 
critical for healthy brain development.13 While there is a range of causative factors that have been 
implicated in AD, including metal ion dyshomeostasis, reactive oxygen species (ROS), membrane 
disfunction, low acetylcholine levels, and tau neurofibrillary tangles, there is still a strong case for 
Aβ and its aggregation to be a causative factor. These factors include a host of familial mutations 
in the Aβ sequence leading to a peptide with an increased aggregation rate and mutations in the 
secretases that cause an increased cleavage of the toxic 42 isoform.14 An occurrence of AD is also 
seen in individuals with trisomy 21, also known as Down syndrome. This correlation is due to the 
APP gene location on chromosome 21. This leads to an increased amount of APP expressed which 
leads to over half of patients developing AD in their lifetimes.  
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This initial hypothesis and investigations into Aβ eventually led to the formation of the 
oligomer hypothesis. The oligomer hypothesis states that it is not the monomer or fibers that are 
the toxic species, instead, it is the oligomers that are created during the formation of fibers that are 
toxic and cause cell death.12,15–17 There is data to support that there is no correlation between the 
total amount of plaques and AD symptoms and a better correlation between symptoms and levels 
of Aβ oligomers.12 In addition, oligomers have also been shown to be toxic to cultured cells. This 
topic will be expanded on in section 1.5 
The Aβ peptide is generated through sequential proteolytic cleavage of APP by beta and 
gamma-secretase (Figure 1.2 A). This cleavage can generate a range of peptide isoforms, with the 
40-residue length peptide being the most abundant and the 42 residues length peptide being the 
most toxic. These peptides are cleaved inside the extracellular membrane and can subsequently, 
be released into the extracellular space.14 Over 90 % of the Aβ that is cleaved from the APP results 
in the 40 residue peptide, with the other percentage being the 42 residue peptide isoform or in other 
 
 
Figure 1.2 Aβ sequence and high-resolution structures. (A) Aβ sequences exist predominantly as 
either 40 or 42 residues through cleavage by beta and gamma secretase on the APP. Alpha 
secretase can occur in the amyloidogenic core highlighted in red, creating a non-amyloidogenic 
peptide. (B) high resolution structure of Aβ40 monomer solved by solution NMR (2LFM). 
Examples of 3-fold and 2-fold symmetry of Aβ40 fibers solved by solid-state NMR (2LMQ  & 
2LMN). Aβ42 fiber structure solved using a combination of Cryo-EM and solid-state NMR 
(5OQV) 
 6 
lengths ranging from 38-43 residues.14 The monomeric peptide is considered and its physiological 
function remains unknown. At neutral pH, the peptide has an overall negative charge of -3 and is 
in an unstructured random coil in solution. The self-nucleating region of the peptide is residues 
16-21, KLVFFA.14 Many of the familial mutations known to cause early-onset AD are located in 
or near this region of the peptide. Alpha secretase, which creates a non-toxic fragment of APP, 
cleaves between the K and L of this region, which breaks up the amyloidogenic core. Aβ fibers 
have been well characterized through a variety of high-resolution methods including solid-state 
NMR, X-ray crystallography, and Cryo-EM. While the overall beta-sheet structure with monomer 
oriented perpendicular to the fiber axis is maintained, a variety of polymorphs have been observed, 
meaning the same overall architecture, but with finite changes in the folding as well as the fold 
symmetry (Figure 1.2 B) 18,19 These polymorphs can exist for a variety of reasons such as sequence, 
mutations, or preparation conditions. While the importance of polymorphism is not fully 
understood, it is thought that these differences in fiber structure may arise from the differences in 
oligomer formation.  
 
1.3 Type II diabetes and hIAPP 
Type II diabetes (T2D) is a widespread disease that affects over 30 million Americans, 
with over 80 million Americans with pre-diabetes. While the exact pathology of T2D is not clear, six 
factors have been identified to contribute to T2D, including insulin resistance, lipotoxicity, endoplasmic 
reticulum oxidative stress, tissue inflammation, amyloid deposition, and β-cell failure of islet cells in 
the pancreas.3,4 While T2D can be reversed if the causes are treated early enough, permanent damage 
to the pancreas can happen via amyloid disruption if left untreated. The early stages of insulin resistance 
causes increased production of insulin. This increase in insulin leads to an increase in the co-secreted 
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peptide, human islet amyloid polypeptide (hIAPP), also known as amylin.20 hIAPP is an amyloidogenic 
peptide hormone. Its normal function is to contribute to satiety after a meal. Normally, it is expressed at 
90:1 insulin to hIAPP ratio and is co secreted in the insulin granules in the β-cells in the islet of 
Langerhans in the pancreas.21 However, in the early stages of T2D, the increased production in insulin 
also increases the amount of hIAPP, increasing their propensity to aggregate.22 The aggregation of 
hIAPP damages cells and amyloid fibers deposit in the extracellular space.23 This can lead to the 
ultimate beta-cell failure associated with T2D, leading to patients no longer producing insulin. While 
hIAPP aggregation is associated with T2D, it is not the only factor contributing to the disease, but its 
importance in animal models has been shown.24 In rat models of T2D expressing their native form of 
IAPP, which does not aggregate due to changes in residues in the amylogenic core, beta cell damage 
does not occur.25 However, in the case of rat models expressing human IAPP, the beta cell damage is 
extensive. 
hIAPP is a 37-residue peptide with a positive charge at neutral pH. It contains a disulfide bridge 
in the N-terminus of the peptide between cysteines 2 and 7. The presence of this bond has shown to be 
 
Figure 1.3 hIAPP sequence and high-resolution structures. (A) 37 residue sequence of hIAPP with 
the amyloidogenic core highlighted in red. A disulfide bridge exists at the N terminus between 
cysteines 2 and 7. The existence of this bond is important for its aggregation kinetics. (B) High 
resolution structures of the hIAPP monomer in solution (5MGQ) and in SDS micelles (2L86) 
solved using solution NMR. Fiber structure of fragment of hIAPP15-25 using MicroED (5KO0). 
No atomic level resolution structure of the full-length fiber exists. 
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important for its aggregation kinetics.26 As with most amyloids it contains an amyloidogenic core of 
residues that nucleate the aggregation, in hIAPP, the residues are NFGAIL from 22-27. hIAPP follows 
the same self-nucleated polymerization mechanism as seen in most amyloid fibers described above. 
While most amyloids are thought to be toxic through the oligomer hypothesis, there is competing 
evidence for hIAPP that the fibers may be the toxic species in vivo models.27 
  
1.4 Amyloid and membrane interactions 
Lipid membranes play a crucial role in a cell’s homeostasis. They are crucial in keeping cellular 
contents from escaping, creating ionic gradients, recruiting cofactors, cell to cell communications, 
bringing together transmembrane proteins by raft localization, trafficking cellular contents and cofactors 
both in and out of the cell. Lipid membranes are susceptible to oxidative stress and can act as a 
mechanism for degeneration.28 Membranes, depending on their composition, can have a dual effect on 
amyloids. Specifically, they can speed up the aggregation mechanism and they are also a medium where 
amyloids can impart their toxic functions.29–35 Amyloidogenic peptides, such as hIAPP and Aβ, are 
known to directly interact with extracellular membranes as well as take on unique confirmations 
once bound.36–38 A general mechanism of toxicity has been proposed and investigated for amyloids 
(Figure 1.4.).31 The first binding of the monomeric peptides’ hydrophobic residues to the lipid 
membrane surface can cause perturbations in the membrane. These initial monomeric binders can 
recruit other peptides to form oligomers that can fully penetrate the membrane causing pores. 
These pores have been shown to allow the flux of ions such as Ca across the membrane, causing 
the cell to lose homeostasis and ionic potential. After the pore formation, continued aggregation 
of the peptides causes full membrane fragmentation via a detergent type mechanism. The 
membrane loses its structural integrity and large biomolecules can no longer be contained.  
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This hypothesis has been much more investigated for Aβ. Anionic lipids, gangliosides, and 
cholesterol have been found to be incorporated into plaques as well as soluble oligomers from 
CSF.39–42 Initial contact to anionic and zwitterionic bilayers has been shown to induce a helical 
conformation of the monomeric peptide portions directly interacting and the portions in solution 
remain relatively unstructured.37 Shorter chain lipids, mimicking lipids that have undergone 
oxidative stress, have been shown to induce toxicity of Aβ and slow down aggregation. While 
most membrane-bound oligomers reported have a beta-sheet structure by both low-resolution 
experiments and simulations,43,44 a high-resolution structure of a membrane-bound oligomer has 
not been solved.  
This membrane toxicity hypothesis is not well investigated for hIAPP. While membrane 
still catalyzes the fiber formation in vitro, evidence for pore formation by oligomers is lacking. 
However, there is also recent evidence that fibers are the toxic species of hIAPP which does not 
fully support the oligomer hypothesis.27 Furthermore, there is evidence that fibers can disrupt 
membranes as well as induce the formation of reactive oxygen species in cells, which is a known 
 
Figure 1.4. Proposed mechanism of amyloid-membrane mediated toxicity. Initial membrane 
surface interactions begin from a hydrophobic region of the amyloid. Aggregation at the membrane 
interface and oligomerization leads to the creation of small pores causing the loss of cell 
homeostasis via ion leakage. further aggregation on the membrane leads to full membrane 
disruption via lipid shedding in a detergent like mechanism allowing for the release of cellular 
contents.  
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cause of toxicity in many diseases including amyloids.45,46 AFM studies have shown hIAPP to 
disrupt bilayer in a detergent-like mechanism after exposure to hIAPP.23,47,48 Recently, high-resolution 
structural studies using NMR revealed a membrane-bound oligomer model of hIAPP of a beta-sheet 
dimer with a similar structure to hIAPP fiber models.36  
1.5 Oligomer hypothesis 
Oligomers are thought to be the toxic species for many amyloid diseases but are yet largely 
undefined.15–17,20,49,50 These small, heterogeneous species, can vary in size and structure and are 
formed during the self-nucleated polymerization mechanism. When monomers interact with one 
another they form small oligomers of various sizes, such as dimers, trimers or higher-order species. 
These smaller oligomers can then interact with other oligomers forming larger species, which may 
then adopt the classic beta-sheet fiber architecture, becoming protofibers. Once the nucleus of 
protofibers have formed, very rapidly full fiber elongation takes place by multiple protofibers 
coming together or addition of monomers or oligomers to the protofiber template.51–56 Once all the 
monomers in solution have been incorporated into fibers, the aggregation has reached the plateau 
phase with highly stable and non-toxic fibers as the result. Throughout these multiple transitions 
of structure and size, the toxic species are thought to exist. 
Some oligomers are proposed to impart their toxic function, in part, by interacting directly with 
the cell membrane of neurons and disrupting the lipid bilayer, permeabilizing the membrane, and 
creating non-selective ion channels and large pores which, in turn, ablate the charge gradient necessary 
for neuronal function.15,30,57–62 Lipid membranes can accelerate the aggregation of Aβ as well as 
facilitate the formation of unique structures of species that are specific to lipid bilayer disruption.63 A 
gap in our structural understanding of many amyloid diseases occurs in oligomers.  Due to their transient 
nature and the structural heterogeneity oligomers have been difficult to isolate and characterize 
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individually.15,32,59 Low-resolution characterization of oligomeric species has been accomplished using 
a variety of techniques including fluorescence-based assays, circular dichroism, AFM and 
NMR.64,65Antibodies have been developed which can target both globular and fibrillar aggregates and 
can be used to probe for specific oligomers over time.66 PICUP utilizes Ru metal oxidation as a way to 
induce radial dimerization among monomers creating covalent bonds that form oligomers which are 
important for learning about sizes of species but subject the peptide to harsh non-physiological 
condition.67 Disulfide bond formation, which requires engineering of mutants to include non-native 
cysteine residues, can stabilize various dimeric forms68 Finally, ESI-IMS-MS is able to determine 
molecular weight and size information of amyloid species treated by inhibitors.69 Lipid nanodiscs have 
been used by varying lipid compositions that slow aggregation to study membrane-bound oligomers.36  
Amyloid toxicity has been implicated in other mechanisms outside of membrane perturbations. 
Fibers are a trap for cellular factors including other proteins or metals as well as be a generation for toxic 
oligomers via fragmentation and nucleation.70 This sequestering can lead to dysfunction in the 
proteasome and autophagy systems.71–73 Oligomers have also been shown to interfere with RNAs 
transport and homeostasis.74 Accordingly, protein aggregation interferes with nucleocytoplasmic 
RNA transport and RNA homeostasis. 75 Aβ specifically has been shown to bind to and interact with 
several extracellular receptors including NMDAR, NGF, insulin, Frizzled and PrPc receptors.76 
Interactions with these receptors have been shown to trigger cellular apoptosis. Aβ oligomer uptake via 
autophagy has been shown to also cause the production of ROS inside of the cell, cause mitochondrial 
dysfunction, among other mechanisms of internal cellular dysfunctions, mentioned previously.77,78 
1.6 Small molecule interactions with amyloids 
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There has been an extensive investigation into small molecules which may modulate the 
aggregation of amyloids.14,79 However, the search for modulators aggregation has relied heavily on 
serendipity; oftentimes, novel classes of small molecules are accidentally discovered and improved 
analogs are subsequently synthesized.80 Similarly, the prevalence of organic dyes in the literature as 
fiber disruption agents81 largely follows from the early development of histological stains for amyloid 
deposits.82 There are generally three different classes of small molecule amyloid modulators which may 
have therapeutic potential or maybe suited as chemical biology tool compounds (Figure 1.5). First, and 
most well-investigated are aggregation inhibitors. These small molecules can bind to monomers 
preventing oligomer formation, direct to off-pathway oligomers that are fiber incompetent, or bind to 
protofibers and prevent full fiber growth.54-77   Second are promoters, which are compounds that can 
increase the rate of aggregation by increasing the transition from monomer to fiber and bypass the 
lifetime of oligomer species.107–109 Last is fiber disaggregators or disrupters, these are small molecules 
that can break down the beat sheet structures of the fibers and resolubilize them to another smaller 
species.106,110–112 The last two categories have been less investigated than inhibitors, due to the original 
oligomer hypothesis causing the prevention of oligomers to be highly investigated, however in recent 
Figure 1.5 small molecule perturbations in amyloid aggregation kinetics. Small molecules are able 
to have multiple effects on amyloid formation (black). Inhibitors (red) added to monomers prevent 
aggregation to complete fiber formation. Promoters (green) added to monomers increase the rate 
of aggregation and push conformation to beta sheet fibers quickly by passing the oligomer state. 
Disaggregators (blue) disrupt the beta sheet fibers and changes the structure back to monomers or 
oligomers that no longer go on the aggregate to beta sheet fibers. 
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years, more exploration has been done into promoters or disaggregators. Recent investigations into 
promotors have come from the idea that fibers are generally nontoxic, and that bypassing oligomer 
formation may reduce the overall toxicity. The investigation into disaggregation comes from the idea 
that fibers may act as a seeding ground for oligomer formation and may act as a sponge for other cellular 
factors and that removing the total plaque load may be beneficial for some amyloid diseases.  
There are a lot of structural similarities among all the compounds that act on amyloid proteins 
(Figure 1.6).  Many of the compounds contain the potential for hydrogen bonding, are aromatic and 
 
Figure 1.6 Structures of identified small molecule modulators of amyloid formation. Inhibitors, 
shown in the red box, is the most explored area of investigation into small molecules and amyloid 






































































































































macrocyclic. 113–115 These characteristics are important for fiber disruption due to the high amount of 
hydrogen bonding and π-πi stacking that is needed for aggregation. Several amyloid modulating 
compounds function on multiple amyloids. For example, one of the most well studied small molecule 
inhibitors of aggregation, EGCG, was originally targeted against huntingtin aggregation in solution; it 
was later found to be active against α-synuclein, Aβ, and hIAPP.  Additionally, O4 was found to be a 
promoter for Aβ as well as a disaggregator of hIAPP.  Methylene blue has also found to be both a 
promoter and disaggregator. 
 
1.7 Biophysical techniques to study amyloids 
Many biophysical techniques are commonly employed to fully monitor the aggregation in 
this pathway.116,117 Fluorescence-based assays such as thioflavin T (ThT) monitor the kinetics and 
solely gives signal based on fiber content. Its fluorescent intensity is increased upon binding to 
beta-sheet content that is highly specific to amyloid fibers. It is often used as the first line of 
investigation into amyloid-related questions but can be misleading depending on ligands added 
and is often difficult to reproduce. Circular Dichroism (CD) monitors protein folding and is used 
for monitoring the random coil to beta-sheet transitions at the beginning and ending of amyloid 
aggregation. Sometimes, an alpha-helical intermediate can be detected but more often the 
heterogeneity of oligomers can get lost and small differences can go undetected and signal 
resolution is poor. Mass spectrometry has been instrumental in providing oligomer sizes as well 
as ligand binding interactions.118 the first model of a membrane oligomer is based on mass spec 
data. Western blotting and dot blotting have been useful in determining fiber epitopes, monomer, 
and oligomers with antibodies such as A11 and OC.119,120 Size exclusion chromatography can 
separate proteins and peptides of a range of sizes and give an estimated oligomer size based on the 
elution volume. Atomic Force Microscopy (AFM) can provide a macroscopic view of aggregation 
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over a range of sizes including large oligomers up to fibers in real-time. It has been useful in 
determining aggregation rates as well as membrane interactions. Transmission Electron 
Microscopy (TEM) and Cryo-EM are quite useful in observing different fibers and their 
morphologies as well as the existence of large oligomers. Recently, high-resolution structures of 
amyloid fibers have been solved using Cryo-EM.121  X-ray crystallography has also been useful in 
the amyloid field for solving fiber and fragment fiber structures. 122 
Nuclear magnetic resonance (NMR) is a very powerful tool for studying many facets of 
amyloid aggregation in both solution and solid states.123–128 Solution NMR is typically used for 
characterizing the beginning stages of amyloid formation while solid-state NMR (ssNMR) is well 
suited for characterizing the end stages of amyloid fiber formation (Figure 1).123 Solution based 
experiments can be used for looking at monomers and low order oligomers. Monomer-monomer 
as well as monomer ligand interactions are commonly studied using simple two-dimensional 
 
Figure 1.7 Biophysical techniques used to study amyloids ordered according to level of resolution 
and limitations based on molecular weight. Low resolution techniques that can be applied to the 
entire aggregation pathway include ThT, CD, dot blot assays, and cell toxicity experiments. With 
increased resolution relative to the previous techniques are AFM and TEM but they can only be 
used for very large oligomers or fibers. Moving to highest resolution for monomers and small 
oligomers is solution NMR, Mass Spec and SEC. Lastly, ssNMR X-Ray crystallography and 
Cryo-EM provides the highest atomic resolution for fibers. 
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experiments such as HSQC or HMQC in which chemical shift perturbation or line broadening 
observations can reveal about specific individual residues’ chemical environments.129 NOE based 
2D and 3D experiments can be used to produce three-dimensional structures of aggregates and 
monomers in early stages of aggregation.36 While solution NMR provides a strong tool, it also has 
its limitations. Restrictions in using NMR in the solution-state are mainly due to the aggregating 
nature of the peptide causing them to become too large over the course of some experiments and 
become NMR invisible due to its decreased tumbling rate. On the other hand, ssNMR experiments 
have been widely used in studying high-resolution structures of fully mature amyloid fibers as well 
as very large oligomers/protofibers that are quite stable or stabilized by freezing.127,130      
1.8 Dissertation objectives 
 While amyloids and their aggregation have been heavily examined in a multitude of facets, 
treatment of diseases caused by them are still absent. A gap in our understanding still exists in the 
interactions of small molecule disaggregation and how small molecules can change the interplay 
between amyloids and membranes. The objectives of this dissertation are to explore these 
questions for hIAPP (chapter 2) and Aβ (chapter 3) respectively. First, I explore how a curcumin 
derivate (CurDAc) can selectively disaggregate and inhibit hIAPP over two other amyloid peptides, Aβ, 
and hCT (Chapter 2). Second, I set out to find new small molecules that can cease aggregation Aβ at 
the membrane interface (Chapter 3). Since most small molecules that are known to be inhibitors of Aβ 
lack activity in the presence of the membrane, I performed a high throughput screen and identified new 
membrane-active inhibitors.  
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Small Molecule Induced Toxic Human-IAPP Species Characterized by NMR 
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Ramamoorthy, A. Small Molecule Induced Toxic Human-IAPP Species Characterized by 
NMR. Submitted 
2.1 introduction  
Transitions from monomer to fiber have been well studied since the beginning of the 
amyloid hypothesis.1 While the monomers and fibers have been well characterized, the transient 
and difficult to isolate oligomers are thought to be the most toxic species in 30 different amyloid 
diseases.2,3 Characterization of oligomers has been a difficult task but strides have been made4. In 
contrast to oligomers, fibers are considered non-toxic, but they have been hypothesized to serve as 
nucleating sites for toxic species formation.5 Therefore, it may be advantageous to remove them 
to reduce the number of nucleation sites.  
Small molecules have been sought out to interact with many different points in the 
aggregation process and can function as inhibitors, promoters, or disaggregators.6–11 These tool 
compounds are advantageous to target many types of biological molecules including amyloids. 
They are highly tunable to the function needed, can bind tightly to the target protein, and can pass 




water-solubility and stability compared to its parent molecule (Figure A.1). It has- been shown to 
inhibit hIAPP both in the presence and absence of lipid bilayers and negate hIAPP’s aggregation-
induced lipid membrane disruption. 17   
In this study, the effects of CurDAc on three different amyloid peptides, amyloid-β (Aβ40), 
human islet amyloid polypeptide (hIAPP), and human calcitonin (hCT), were examined. While 
these three peptides have similar polypeptide length ranging from 32-42 amino acids, they differ 
in their isoelectric point, hydrophobicity, and aggregation kinetics (Figure A.2). These similarities 
and differences make them ideal for understanding the structural specificity of small molecules. 
NMR spectroscopy is ideal for studying these types of systems because of the residue-specific 
structural information that can be gained from the experiments. When NMR is coupled with other 
biophysical techniques, the kinetics, protein structure/fold, and protein interactions of the isolated 
species can be understood. Integrating these experiments with cell-based assays, further 
information can be gained on how these species can act towards disease-relevant cells. Here, we 
show the use of CurDAc to generate a toxic oligomer of hIAPP which arises from both monomer 
interactions and fiber disruptions, and we compare how this small molecule acts against two other 
amyloids. 
2.2 Results and Discussion 
Fiber growth was monitored by utilizing Thioflavin-T (ThT), which is a widely used 
fluorescence reporter for amyloid fiber formation that gives kinetic and mechanistic information 
about amyloid aggregation (Figure 2.1A-F). 18,19 Using ThT fluorescence assays, both inhibition 
and disaggregation profiles were obtained for all three peptides, hIAPP (Fig.1 A&D), Aβ40 (Fig. 1 




amyloid peptides, it displayed a distinct difference in potency. For hIAPP, as the concentration of 
CurDAc was increased from 0.06 to 2 molar equivalents, the overall final ThT signal intensity 
with respect to the control decreased indicating a decrease of fiber formation (Figure 2.1A). Not 
only is the overall intensity lower, but also the slope of the elongation phase is extended, indicating 
a possible change in the secondary nucleation step.18 CurDAc acted as a fibrillation inhibitor for 
hCT as well; however, it was not as effective with hIAPP. For Aβ40, the concentration range that 
was tested on hIAPP and hCT did not affect the inhibition of fibril formation (Figure 2.1C). 
Superstoichometric ratios (10-15 molar equivalents) were needed to see a depression of fibril 
formation in Aβ40 (Figure 2.1C). Interestingly, the lag time at lower equivalencies of CurDAc was 
decreased by about 200 minutes, an effect that was not observed with the other two peptides. We 
 
Figure 2.1 Inhibition and disaggregation of amyloid peptides by CurDAc.  ThT fluorescence 
inhibition curves of hIAPP, hCT and Aβ40 (A-C respectively) in the presence of varying molar 
equivalents of CurDAc. Disaggregation curves of hIAPP, hCT and Aβ40 (D-F respectively) using 
the same molar equivalents as the inhibition experiments. Red arrow indicates when CurDAc was 
added. All experiments were done in pH 7.4 phosphate buffer with slow orbital shaking at 25°C 
for hIAPP/hCT and 37°C for Aβ40. 
 










































































































































believe that the change in kinetics based on the concentration of CurDAc is due to a colloidal 
inhibition effect and charge-charge repulsion of CurDAc with Aβ40.20,21  
Amyloid disaggregation as a method of removing plaque loads could be an avenue to 
reduced toxicity since plaques have been hypothesized to serve as nucleating sites for toxic 
oligomers.22 Despite their innate hyperstability, amyloid fibrils have been shown to be 
disaggregated by harsh methods including heat, pH, and organic solvents as well as small 
molecules, peptides, antibodies, and proteins.9,23–26,26–30 In terms of small molecules, most fibers 
require molar excess of the disaggregating compound for disassembly. In Figure 2.1D, ThT curves 
show the disaggregation  of hIAPP fibers upon the addition of CurDAc (red arrows) in the same 
stoichiometric ratios of CurDAc as in the inhibition experiments A similar trend is seen for hCT 
in that there is an immediate drop in ThT intensity followed by a decline and plateau, however the 
steepness of decline is much stronger and the curve plateaus much quicker compared to that 
observed for hIAPP (Figure 2.2E). For Aβ, we unexpectedly saw drops in intensity for all of the 
equivalents examined, however, these curves have no increase or decrease in intensity after the 
initial drop (Figure 2.2F). The initial steep decline in ThT intensity is followed by an eventual 
plateau. To rule out the possibility of ThT displacement we repeated these same experiments with 
higher excess of ThT and the same trend was observed (Fig. S3), leading us to believe that another 
mechanism is at work. Using Isothermal Titration Calorimetry (ITC), the binding of CurDAc to 
Aβ40 or hIAPP was studied to further investigate the nature of the interaction (Figure A.4 and Table 
A.1). In the ITC experiments for hIAPP, no interaction was observed between hIAPP monomers 
and CurDAc. CurDAc interaction with hIAPP fibers was found to have a dissociation constant 




concentrations of CurDAc (Figure A.10). This data further supports that the disaggregation effect 
is not a result of ThT displacement given the very similar binding constants of CurDAc to hIAPP 
fibers (~7µM) and ThT to amyloid fibers (~10 µM). 31 
Building on the ThT data of selectivity and potent disaggregation of hIAPP, we looked to 
NMR to provide us with a deeper understanding of this interaction. By looking at the total proton 
NMR signal intensity of hIAPP in solution we analyzed the aggregation kinetics of hIAPP 
monomers in the presence of CurDAc (Figure A.5). Since large aggregates (typically >100-kDa) 
do not contribute to the narrow spectral lines observed in solution NMR experiments, the measured 
1H NMR intensity should be inversely proportional to the amount of aggregated hIAPP peptide 
present in the sample. For example, it has previously been shown that sigmoidal intensity decay 
plots indicating monomer depletion due to the self-assembly process to form amyloid fibers can 
be used to determine the kinetics and mechanisms.32–34 Interestingly, hIAPP in the presence of 
CurDAc at neutral pH loses signal intensity faster than in the absence of CurDAc. Most of the 
peaks in the NMR spectrum disappeared within 10 hours for the peptide alone.  In the presence of 
CurDAc, the peaks in the NMR spectrum disappeared in less than one hour, indicating the 
formation of NMR invisible species, such as a large off-pathway oligomer. 35  hIAPP is an unstable 
peptide under in vitro conditions, which is in accordance with quick self-assembly of the peptide 
to form aggregates under neutral conditions. 36 It is also known that the formation of the N-
terminus disulfide bridge is important for its aggregation kinetics, and in this NMR study, the 
oxidized form of hIAPP is used throughout. Due to the accelerated aggregation and signal loss at 
neutral pH, we lowered the sample pH to 5.3, which is the physiological pH of hIAPP when stored 




to perform longer NMR experiments on hIAPP and enabled us to do additional analyses of the 
interaction with CurDAc due to the increased lifetime of the monomeric sample. The net-charge 
of hIAPP becomes slightly more positive at pH 5.3, due to a greater portion of H18 residues 
becoming protonated. At this pH, hIAPP stayed relatively soluble for 30 hours with only 20% 
signal loss (Figure A.5 and A.6). At a 1:1 molar ratio with CurDAc, the hIAPP signal decreases 
 
Figure 2.2 hIAPP monomer and CurDAc interactions characterized by NMR. (A) 2D 1H/15N 
SOFAST-HMQC spectra exhibiting the interaction between 100 µM hIAPP(black) with 100 µM 
CurDAc (red) at pH 5.3 acetate buffer. (B) Chemical shift perturbations for the backbone amide 
15N and proton resonances as a function of the amino acid sequence position. The dashed line 
indicates the mean for the observed CSPs with the stronger shift changes above 0.015. (C) 
Monomer structure of hIAPP (PDB:5MGQ) solved by NMR experiments at pH 5.3 is used in this 





more rapidly with 70% of the signal lost after 20 hours with complete signal loss at 40 hours 
(Figure A.5). This observation suggests that CurDAc can quickly initiate hIAPP aggregation and 
inhibits the fibrillar structure morphology of the aggregate species in the same way as other 
flavanols and confirms our initial observations using other biophysical methods.11  
  Using two-dimensional NMR techniques, such as SOFAST-HMQC, it is possible to obtain 
residue-specific information of the CurDAc-hIAPP complex interaction (Figure 2.2A). Chemical 
shift perturbations (CSPs) are a valuable tool for characterizing protein-ligand interactions, even 
if the chemical shift changes are very small.38 In comparison to the reference 1H/15N HMQC 
spectrum of hIAPP alone, small CSPs were observed, in CurDAc containing samples, for residues 
in the N terminal and central regions as indicated by the peaks above the (horizontal) dashed line 
indicating the mean (Figure 2.2 B). Most strongly affected residues include T4, C7, A8, Q10-N14, 
L16-S19, I26, and S29 and are highlighted on the monomeric structure (Figure 2.2C).39 One of the 
highly affected residues, H18, is known to be important for its aggregation and toxicity.40,41 Most 
of these residues are neither aromatic nor carry a charge, indicating that the mechanism of action 
is most likely not due to electrostatic or pi-pi interactions. Interestingly, we were able to identify 
that the CurDAc causes an effect not only at the N terminus but also in the central region, 
specifically near the GAIL sequence (residues I26 and S29) which is the nucleating region for 
amyloid aggregation.42 Using three different kinds of software to predict secondary structure, the 
Random-Coil Index, Secondary Structural Propensities database, and the Delta-Delta of the C  
chemical shift, the C , CO, HN chemical shifts were analyzed and are shown in Figure A.7.43,44 
All three approaches predict that the N-terminus of hIAPP has an alpha-helical conformation, with 
a slight beta-sheet tendency near the amyloidogenic core (residues 24-27) and the remainder of the 




could explain why CurDAc inhibits fibril formation, due to the possible lack of a beta-strand for 
self-recognition and steric zipper formation by this essential sequence.   
Fibers represent a large insoluble form that is invisible for the traditional solution NMR 
experiments due to the anisotropic interactions, such as dipolar couplings and chemical shift 
anisotropy not being fully averaged out which induces line broadening.45,46 In the event that 
portions of the peptides that form the fibers start to become soluble and can tumble sufficiently 
fast in the solution, the peptide signal will become sharp and the newly soluble peptide species can 
be identified and quantified. The starting NMR spectrum of the hIAPP fibers can be seen in Figure 
2.3A in black, in which very few peaks were observed. 72 hours after the addition of CurDAc, 
strong peaks appeared in the spectrum as shown in the amide region (red) of the NMR spectrum. 
As shown in Figure 2.3C, after the addition of CurDAc to fibers, the signal intensity for the peaks 
observed in the proton NMR spectrum raised steadily over 72 hours. 
By using 2D SOFAST-HMQC NMR experiments, we were able to identify some of the 
peaks which appeared after 72h of adding CurDAc to hIAPP fibers. These resonances are 
attributed to mobile regions of the peptide and the disrupted aggregates of hIAPP fibers in solution 
(Figure 2.3B). 3D HNCA and 3D HNCOCA experiments were performed to identify some of these 
residues that appeared in the spectra of CurDAc-induced disaggregated hIAPP species (Figure 
A.8). The 2D and 3D NMR spectra were not straightforward in their characterization due to the 
low concentration of disaggregated species which contributes to the observed NMR signal. 
However, these experiments do allow us to determine some of the residues and regions of hIAPP 
that have become visible as a result of disaggregation. From our partial assignment, we have 




residues were also identified as residues affected by CurDAc interactions with hIAPP monomers 
by CSPs (Figure 2.2B). 
Figure 2.3D shows the model of the amino acid sequence with the highlighted residues in 
red being the ones identified by the disaggregation of fibers. Out of the identified residues, V17-
N21 are sequentially grouped, while A8, L12, and I26 are distributed randomly. While we were 
able to assign most of the visible residues signals, a few signals remained unassigned. It is possible 
that these unassigned peaks may belong to other residues that are near the three randomly 
distributed residues (A8, L12, I26).  
 
Figure 2.3 NMR monitors disaggregation of hIAPP fibers. (A) Proton NMR spectra of 90 µM 
hIAPP fibers (black) and 90 µM hIAPP with 90 µM CurDAc after 72-hour incubation with 
CurDAc (red) at pH 7.4 in phosphate buffer. (B) 2D 1H/15N SOFAST-HMQC NMR spectra of 
hIAPP monomers (black) and the disaggregated species (red) at a 1:1 peptide:CurDAc molar 
ratio. Peak assignments of the monomer are also shown for reference. (C) Normalized overall 
proton peak intensity of hIAPP fibers as a function of disaggregation by CurDAc over 72 hours. 
(D) Amino acid sequence model of hIAPP with highlighted residues identified after CurDAc 
disaggregation in red. (E) Chemical shift perturbations for the backbone amide 15N and proton 
resonances of the identified residues in reference to that of monomers. (F) TEM images of hIAPP 





The residue H18 was identified in both the monomer interaction with CurDAc and as a 
mobile residue after disaggregation of fibers by CurDAc, and it is known to be a key residue in 
contributing to the toxicity of hIAPP.[40 The residues located in the N terminus are shown to 
interact with CurDAc and they are important for the initial contacts in self-assembly. 47,48 When 
comparing the visible residues to known hIAPP monomer and fiber structures, residues V17-I26 
can all be found in a loop region of the peptide. 39,49,50 Due to this we believe there are two 
possibilities for the absence of other residue signals. One possibility is the residues are in a highly 
flexible/mobile loop region of an oligomeric structure, while unseen residues are buried within the 
oligomer causing NMR signal loss.45 The second possibility is that while a smaller species is 
becoming disaggregated, they are exchanging between bound and unbound states from the larger 
fiber structure. This could cause a broadening of the residues that were not identified in the 
spectrum, making only these highly mobile loop residues visible which are not in exchange.51 
Figure 2.3E shows the chemical shift perturbations of the identified residues. 6 out of the 8 residues 
have a significant upfield shift in the proton dimension and a downfield shift in the nitrogen 
dimension indicating a drastically different chemical environment as compared to the monomer. 
These chemical shift values do not fall in the typical range of known secondary structural chemical 
shifts for these residues.52 The CurDAc induced disaggregation of hIAPP fibers was corroborated 
using TEM (Figure 2.3F). TEM shows the difference between hIAPP fiber morphology before and 
after the addition of CurDAc. The disruption of aggregates increases over time as seen with the 
decreasing amount and size of hIAPP fibers indicating the fiber disaggregation.  
Thus, our NMR experiments demonstrate the ability of CurDAc to disaggregate fully 
matured amyloid fibers of hIAPP, which is in excellent agreement with ThT based fluorescence 




resulting from the interaction of CurDAc with hIAPP fibers. However, the poor S/N and the 
absence of a complete set of resonances in the NMR spectra dampened our efforts in determining 
the high-resolution 3D structure of CurDAc induced disaggregated hIAPP species. Therefore, the 
development and application of approaches to enhance the S/N for NMR studies on such samples 
could be worthwhile as they can be useful to study a variety of amyloid proteins and their 
interaction with small-molecule compounds. Nevertheless, the NMR results reported in this study 
provide rare insights into the formation of an off-pathway hIAPP species and reveal the key amino 
acid residues that are solvent-exposed and may be a part of a larger complex. 
Given this exciting NMR data, we turned to other biophysical techniques to support our 
findings. By recording CD spectra of hIAPP overtime after the addition of CurDAc, the secondary 
structural changes associated with the disaggregation of fibers could be monitored. Before the 
addition of CurDAc, a strong peak was observed at 218 nm indicating a beta-sheet conformation 
(Figure A.9). There was also a shoulder at 200 nm, which could indicate a portion of the peptide 
remaining in random-coil. Using CD fitting software, BeStSel, we analyzed the data to understand 
the possible distribution of conformations in the samples (Table A.2).53 While a majority of the 
structural content was determined to be a beta-sheet, after the addition of CurDAc a small helical 
conformation was observed between 30 minutes and 40 hours of the ongoing fiber dissociation. 
For Aβ40 and hCT, CD experiments indicated the formation of a stable beta-sheet secondary 
structure in the same time span as the ThT curves which was maintained after the addition of 
CurDAc (Figures S10).  
The CD samples were examined using TEM and fibers were observed for all three different 




monitored TEM over an extended time in accordance with the NMR and CD experiments (Figure 
A.9) in which the remodeling observed in the former techniques can be visualized. For hCT after 
the addition of CurDAc, more amorphous type aggregates can be seen after remodeling with two 
molar equivalents (Figure A.11). For Aβ40, the fibers maintained their architecture at 10 molar 
equivalents of CurDAc but appeared to be overall shorter in length than before addition (Figure 
A.11).  
There is considerable interest in understanding cellular toxicity of amyloid species in order 
to evaluate the potency of small-molecule amyloid inhibitors and potentially to develop 
 
Figure 2.4 Cell toxicity measurements of hIAPP monomer and fibers in the presence and absence 
of CurDAc. RIN-5F cell viability measured by MTT reduction in the presence of hIAPP 
monomers and fibers without CurDAc and after 24-hour incubation with CurDAc (A-B). Cell 
toxicity final intensity after 13 hours of monitoring by CellTox Green fluorescence (C-D). 5, 1 
and 0.5 µM peptide were used for all experiments in the presence or absence of 1 molar equivalent 
of CurDAc. Ordinary one-way ANOVA tests with Tukey’s multiple comparisons were performed 
in respect to cells treated with hIAPP in the presence or absence of CurDAc, ****p<0.0001, 
indicate levels of significant differences. Data is shown as mean +/- SD with N=5 or 3 independent 





compounds to treat the related amyloid disease. While fibers are thought to be relatively inert, 
cytotoxic species are pointed at pre-fibrillar oligomers in the case of many different amyloid-
related diseases. In this study, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) dye reduction assay was utilized, which requires the conversion of MTT to formazan via 
mitochondrial enzymes indicating metabolic health (Figure 2.4). Freshly prepared monomers, or 
fibers grown for 24 hours, were added to the rat pancreatic islet cell line, RIN-5F, at varying 
concentrations and were allowed to incubate with adherent cells for 24 hours before measuring 
toxicity. It was found that the fibers exhibited greater toxicity than the monomers by decreasing 
the cell viability by greater than 40 percent at the highest concentrations used. When monomers 
and fibers were treated with CurDAc after 24 hours, the toxicities of both were increased in 
comparison to the non-treated samples. The toxicity of fibers increased by about 15 percent when 
disaggregated and the monomers increased upwards of 20 percent for all the concentrations. It is 
interesting to note that the toxicities of both monomers and fibers treated with CurDAc, exhibited 
very similar levels of toxicity indicating a level of similarity between the two. The toxicity of 
CurDAc to its parent compound curcumin was also compared, and it was found that both were 
nontoxic by the MTT assay (Figure A.12). To corroborate our findings using the MTT assay, the 
CellTox Green assay was utilized (Figure 2.4 and A.13). This assay was in agreement with MTT 
results, in which we observed increased toxicity for the peptide that had been treated with CurDAc 
after 13 hours of incubation. These results indicate co-incubation of hIAPP monomers or fibers 
with CurDAc promotes the formation of toxic species. Statistical significance calculations were 
performed using ordinary one-way ANOVA tests with Tukey's multiple comparisons. All values 





While amyloid aggregation has been extensively studied, the use of small molecules as a 
chemical biology tool provides advantages to traditional methods of stabilization. This study has 
shown the potential of CurDAc to act as a peptide-specific chemical probe to study hIAPP and to 
disrupt fully mature fibers and prevent monomers from forming fibers. This is the first example in 
the literature of using NMR to follow fiber disruption at atomic resolution which allowed us to 
identify solvent-exposed residues in the species formed after disaggregation. Most of these 
residues, which are in the loop regions of known monomer and fiber structures, have distinct 
chemical shifts. This suggests that these residues are in a new chemical environment and/or 
structurally distinct and may be part of a larger oligomeric species that is not visible for solution 
NMR studies. TEM served as a visual confirmation in which the fibers can be seen being broken 
down upon incubation with equimolar amounts of CurDAc. Notably, these disaggregated species 
were more toxic than the fibers or monomers to cultured cells. We believe that the results reported 
in this study can be used to provide a starting point to develop other small molecules for the 
purpose of amyloid modulation or oligomer characterization. Using tool compounds like CurDAc 
could provide new avenues to probe and isolate the pathways of oligomer formation, which may 
lead to further understanding of the toxic oligomer hypothesis.  
2.4 Experimental Section 
2.4.1 Materials and Reagents  
All reagents were purchased from commercial suppliers and used as received unless noted 
otherwise. Aβ40 was purchased from BioBasic (Markham, ON, Canada) at >95% purity and used 




purity and used without further purification unless otherwise noted. Human calcitonin peptide was 
synthesized via FMOC chemistry as described previously. To ensure consistent monomeric 
starting conditions, peptides were dissolved in hexafluoroisopropanol (HFIP) at a concentration of 
1 mg/ml and then lyophilized for 48 hours. Powders were kept at -80 C until needed for 
experiments.  CurDAc was synthesized in the same method as previously described.17 All other 
reagents were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A).  
2.4.2 Thioflavin-T Assay.  
hIAPP monomer sample was prepared by dissolving the lyophilized peptide either dilute HCl at 
pH 4 (hIAPP) or buffer (hCT and Aβ40) to a stock concentration between 150 – 200 µM, kept at 0 
ᴼC (ice), vortexed for 15 s. and bath sonicated (at 0 ᴼC) for 1 min. Fresh monomer samples were 
diluted into Phosphate buffer (pH 7.4) containing 50 mM NaCl for each subsequent experiment. 
The kinetics of amyloid formation were monitored by the fluorescent, amyloid-specific dye ThT. 
All samples were prepared by diluting the stock solution to a final concentration of 10 µM in the 
presence of 20 µM ThT. Samples were plated in triplicate on Corning 96- well plates, maintained 
at 25 C (hCT and hIAPP) or 37 C (Aβ40), and subject to continuous, slow orbital shaking. 
Fluorescence readings were taken on a Biotek Synergy 2 microplate reader and were read from the 
bottom with an excitation wavelength of 440 nm (30 nm bandwidth) and an emission wavelength 
of 485 nm (20 nm bandwidth) at three-minute intervals. For studies exploring fibril remodeling, 
fibrils were initially formed in the 96-well plate for 24 h. After mature fibrils were formed CurDAc 
was added directly to wells at varying concentrations, diluting the volume by less than 1% to 




used to monitor fibril formation. After data acquisition, raw fluorescence values were background 
subtracted and then normalized.  
2.4.3 Circular Dichroism 
 Single point CD measurements were carried out at a concentration of 40 µM peptide in the absence 
or presence of varying concentrations of CurDAc. CD measurements were performed on a JASCO 
J- 1500 CD Spectrometer using a 0.1 cm path length cell. Spectra were acquired at 25 °C using a 
bandwidth of 2nm, a scan rate of 200 nm/min, and averaging spectra over 5 scans with a smoothing 
factor of 11. Measurements were taken immediately after mixing the sample (t = 0 h) and after 
various time points at 25 °C (hIAPP and hCT) or 37 °C (Aβ40) under slow orbital shaking 
(conditions mimicking those used in ThT kinetic assays). hIAPP time course disaggregation 
experiment was analyzed using BeStSel using the multiple spectra analysis tool with a scaling 
factor of 10. 
2.4.4 Transmission Electron Microscopy 
 Samples used in TEM analysis were taken directly from the time course CD experiments after 
24h incubation (both for the modulation of fiber formation and the remodeling of preformed 
fibrils). Glow discharged grids (Formar/carbon 200 mesh, Electron Microscopy Sciences, Hatfield, 
PA, U.S.A.) were treated with samples (7 µL) for 2 min at room temperature. Excess buffer was 
removed via blotting and then washed three times with dd H2O. Each grid was then incubated with 
uranyl acetate staining solution (1% w/v in ddH2O, 7 µL) for 1 min, and excess stain was blotted 





2.4.5 Cell Toxicity Experiments  
RIN-5F(ATCC# CRL-2058 batch number 61465080) cells were grown in RPMI-1640 media with 
2 mM L-glutamine supplemented with 10% fetal bovine serum in a humidified incubator at 37 °C 
with environment of 5% CO2. Cells were kept between passage numbers below 25. 10-cm cell 
culture dishes were used for culturing, and 96 flat bottom well trays for the MTT assays. Cells 
were plated at 50,000 cells per well in 90 µL and were allowed to adhere for 24 hours. 
To prepare hIAPP fibrils to be used in cell toxicity experiments, lyophilized hIAPP monomer was 
solubilized in Milli-Q water brought to pH 4 using HCl and diluted to appropriate concentration 
using 20 mM Phosphate buffer (pH 7.4) containing 50 mM NaCl. Peptide was then treated with 1 
equivalent of CurDAc. Peptide was incubated for 24 hours at room temperature with shaking at 
750 rpm to form fibrils. Monomer was freshly dissolved in the same manner and then diluted in 
buffer. 10-fold stocks of peptide were added to each well at 10 µL for a final volume of 100 µL. 
After 24-h incubation of cells with aggregates, the MTT cell proliferation assay (Promega, G4000) 
was used to determine the toxicity of samples following the manufacturer protocol. 10 µL of the 
MTT dye solution was added to each well and set to incubate at 37 °C for 3-3.5 hours. 100 µL of 
stop solution was added and set to incubate for 12 hours. The absorbance of each well as then 
measured at both 570 nm and 700 nm (700 nm for background correction). All cellular viability 
values were normalized to cells treated with buffer. Values reported are the average of five 
independent trials and the error is reported as the standard deviation of these averages. 
CellTox Green Cytotoxicity experiments were performed as per the manufacturer’s suggestions 
(Promega G8741). Cells were plated at 50,000 cells per well in a 96 well plate. Peptide and 




after the addition, the plate was put in a FLUOstar omega plate reader equipped with an 
atmospheric control unit kept at 37 °C with 5% CO2 and 20%O2. The plate was read every 10 
minuets at 485ex/520em. All cellular toxicity values were normalized to cells treated with buffer. 
Values reported are the average of three independent trials and the error is reported as the standard 
deviation of these averages. Ordinary one-way ANOVA tests with Tukey’s multiple comparisons 
were performed.  
2.4.6 NMR Experiments  
All NMR experiments were performed at 25 °C, employing Bruker Avance 500 and 850 MHz 
spectrometers, equipped with cryogenic probes. Referencing of the proton chemical shifts to the 
water resonance frequency, the 15N and 13C shifts were referenced indirectly. Almost complete 
backbone assignments were obtained using triple resonance assignment experiments helped from 
Non Uniform Sampling approach.54,55  NMR spectra were processed using the software TopSpin 
(Bruker). Spectra were analyzed using ccpNMR analysis.56 CSPs were calculated in respect to 
each nuclei. 57 The signal intensity of disaggregation experiments were found by taking the 
intensity of the final FID and normalizing it as maximal amount dissolved over a course of the 
experiments.  
NMR Sample preparation Lyophilized powder of the recombinant human IAPP(1-37) produced 
as mentioned in our previous protocol  was dissolved into NMR buffer (30 mM deuterated acetic 
acid buffer, pH 5.3) to yield a final peptide concentration of maximal 100 µM.58 For the case of 
phosphate buffer or the powder was dissolved in 100 µL of the acetate buffer and diluted until 500 
µL with the buffer selected. Phosphate buffer contain 50 mM sodium phosphate with pH 7.4 and 




10 % D2O. The samples were measured and stored at 25 °C. For the NMR sample of the fibrils, 
the peptide was initially dissolved in 30 mM deuterated acetic acid, pH 5.3. To prepare the peptide, 
the solution was mixed with phosphate buffer contain NaCl at pH 7.4 and the sample was incubated 
for approximately 12 h at room temperature.  The CurDAc Solution was prepared into water to a 
high concentration of 10 mM and mixed with the IAPP as required. The sample was transferred in 
a NMR tube for solution-state NMR measurements.   
2.4.7 Isothermal Titration Calorimetry  
Isothermal titration calorimetric experiments were performed with a VP-ITC instrument (Marvern 
Instrument, UK). The concentrations of CurDAc in the ITC syringe was 1mM for fiber 
experiments or 500 µM for monomer experiments. The concentration hIAPP was 30 µM and Aβ40 
was 100 µM in the ITC cell. 10 mM phosphate buffer (pH 7.4) with 100 mM NaCl was used. 
Titration experiments consisted of 19 injections spaced at 300/600 s intervals for fibers and 100s 
interval for monomer.   Injection volume and injection duration was 0.2 µl for 0.4s and 2 µl for 4 
sec. fibers were stirred at 1000 rpm and monomer at 750 rpm with reference power of 5 µcal/sec 
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High Throughput Screening at the Membrane Interface Reveals New Inhibitors of 
Amyloid-β 
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F., Stoddard, A.K., Ivanova, M.I., Ramamoorthy, A. High Throughput Screening at the 
Membrane Interface Reveals New Inhibitors of Amyloid-β. Submitted 
3.1 Introduction 
Alzheimer’s disease (AD) is a deadly and debilitating ailment that currently affects 50 million 
people worldwide.1 Early research into AD focused on the presence of indicative protein amyloid-
beta (Aβ) fibrils due to their prominence in postmortem examination of patients’ brains. However, 
it is now hypothesized that small, toxic, intermediate species, known as oligomers, are the 
predominant toxic amyloid-beta (Aβ40) species in AD.2 Aβ peptides are produced from the 
cleavage of amyloid precursor protein (APP) in the extracellular membrane by β and γ-secretases. 
Cellular membranes have been implicated to be a site of potential toxicity and can act as a catalyst 
for amyloid aggregation.3  Some oligomers are proposed to impart their toxic function by 
interacting directly with the cell membrane of neurons then disrupting and  permeabilizing the 
membrane. As a result, non-selective ion channels and large pores are created which, in turn, ablate 
the charge gradient necessary for neuronal function.4 Many studies suggest that lipid membranes 
are able to accelerate the aggregation of Aβ as well as facilitate the formation of unique structures 
of Aβ species that are specific to lipid bilayer disruption.5 
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 There has been extensive investigation into small molecules with the ability to modulate 
the aggregation of Aβ in solution.6  However, the search for modulators of Aβ aggregation has 
relied heavily on serendipity; often times, a novel class of inhibitors is accidentally discovered, 
and improved analogues are subsequently synthesized.7 Relying on accidental discoveries is 
unlikely to generate a diverse enough chemical portfolio to successfully generate a drug candidate 
that can demonstrate clinical efficacy. Thus, it is essential to identify new and novel chemical 
species which may be specifically capable of modulating membrane-assisted Aβ40 aggregation for 
use as toxic Aβ oligomer probes.2  Here, through the usage of a small molecule library, 5 
compounds have been identified that modulate the formation of Aβ40 aggregates in the presence 
of lipid membrane. These small molecules represent an avenue for the development and further 
investigation of Aβ40 and membrane interactions. 
3.2 Results and Discussion 
Using a library of over 1,800 compounds, selected for their chemical diversity and 
biological activity, the screening was performed by the addition of Aβ40 in the presence of large 
unilamellar vesicles (LUVs) composed of a mixture of 7:3 molar ratio of DOPC:DOPG, which  
represents the charge distribution of eukaryotic membranes (Figure 3.1A). To probe the 
interactions between the lipid bilayer, small molecules, and Aβ40, we used a fluorescence readout 
assay regularly employed in amyloid studies using Thioflavin-T (ThT) dye. ThT assays provide 
insights into the kinetics of amyloid formation, which facilitates the identification of compounds 
that are able to inhibit the formation of β-sheet rich amyloid aggregates. Signal intensity can be 
proportional to the fibers present and decreases in intensity can be indicative of a decrease in 
overall fiber content (Figure B.1). We optimized screening conditions, achieving a Z-score of 0.46 
(Figure 3.1C). 40 reproducible hits were selected after ruling out initially fluorescent compounds 
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and compounds which did not give a matching read-out in twin sets of plates. These 40 compounds 
were then used for a concentration response curve (CRC) titration screen to determine the activity 
of the compounds in a range of concentrations (Figures B.2 and B.3). Results from the CRC screen 
helped us to narrow down the 40 initial hits to 21 primary hits based on the calculated IC50 values 
and the exclusion of known compounds with PAINS properties (Figure 3.2, Tables B.1 and B.2).7 
Structural similarities exist among the 21 hit compounds. Many are heterocyclic, planar and 
contain functional groups capable of hydrogen bonding, properties which have been identified to 
be important in amyloid modulation. The compounds were given abbreviations based on 
similarities and functional groups: Anthroquinone/naphthoquinone (AQ), benzendiols (BD), 
benzofuran (BF) Tetrahydroquinoline (THQ), thiourea (TU), and dihydroquinazolin (DHQ). 
While some of these compounds have been previously reported as inhibitors of other amyloid 
peptides, none have been identified to inhibit membrane associated aggregation. 
 
Figure 3.1. (A) An illustration of the components of the screen: Aβ40 monomer (2LFM), LUVs, 
small molecules and ThT. (B) schematic of reading the assay plates before aggregation and then 
heating and shaking the plates before reading the final fluorescence intensity after 24 hours of 
incubation. (C) Percent Inhibition as calculated from final fluorescent intensity of every 
compounded screened for inhibition. Value of twin plates are averaged and normalized in respect 
to the positive (red line) and negative controls (blue line). 
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The selected 21 compounds were first subjected to full ThT kinetic profiles with 
measurements taken every 5 minutes (Figure 3.3). Each compound was tested at 10, 5 and 2 molar 
equivalents in respect to the concentration of Aβ40 while in the presence of 500 μM LUVs. Initially 
by the ThT assay, many appear to be promising and robust inhibitors, with many compounds 
negating the aggregation fully at all the concentrations tested. Some interesting kinetic traces were 
also observed from compounds that didn't inhibit fully i.e. THQ-1, THQ-3, TU-1, DHQ-2 and BF-
4. THq-3 and BF-4 extended the lag time at higher concentrations, indicating changes in the 
primary nucleation steps. TU-1 and DHQ-2 showed a decrease in the final fluorescence intensity 
but the lag time remained the same, pointing to a change in secondary nucleation. THQ-1 
demonstrated interesting kinetics with an increase and decrease in intensity. These unusual kinetics 
could indicate that THQ-1 has preferential interactions with amyloid fibers, acting like a 
disaggregator, or that the structure of the aggregates is ThT active but then evolves into something 
that is no longer able to bind to ThT.  
 
Figure 3.2. 21 primary small molecule hits chosen after initial screen and CRC testing. 
Compound abbreviations were given based on similarities between functional groups and can 
be found in Table B.1. 
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However, as critical as the ThT assay is to studying amyloid aggregation, it is also subject 
to fluorescent quenching, overlap, or displacement by other compounds. Because of this, 
secondary confirmation not relying on fluorescence was performed to further narrow down the hit 
compounds. To do this we used the dot blot assay utilizing the OC anti-amyloid fiber antibody, 
which is known to bind to the general amyloid fiber β-sheet epitope (Figures 3.4 and B.4).9 While 
many of the compounds looked to be complete inhibitors by the ThT assay, the strong antibody 
reactivity observed for Aβ40  in the presence of 7 out of the 21 compounds indicated that they do 
 
Figure 3.3. ThT fluorescence kinetics for the 21 selected compounds from CRC testing. 10 μM 
Aβ40 was mixed with varying concentrations of small molecule (10, 5, & 2 equivalents) and 500 
μM LUVs in 20 mM phosphate 50 mM NaCl buffer at 37 °C with slow shaking. 
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not inhibit fiber formation. After identifying compounds that interfere with ThT, we then examined 
the compounds that gave 50% or less reactivity by the dot blot assay by examining them via 
Transmission Electron Microscopy (TEM) (Figure 3.4). We also selected a single compound, BD-
3, to validate that the OC antibody did not give a false positive response, and saw fibers on the 
grid. Out of the 15 compounds investigated, 5 of them inhibited Aβ40 fibers, thus AQ-4, THQ-1, 
BF-3, DHQ-1 and DHQ-2, were selected for a deeper investigation. THQ-1, DHQ-1 and BF-3 
were more uniform in the appearance of the aggregates while DHQ-2 and AQ-4 looked 
amorphous. Of the other 9 compounds that had fiber formation identified at this stage, many of 
 
 
Figure 3.4. (Top) Signal intensities from the dot blot assay using the OC antibody. Samples were 
measured after ThT experiments with 5 equivalents of a compound in respect to Aβ40. Red line 
indicates 50% signal. (Bottom) TEM images of compounds that gave less than 50% antibody 
reactivity from the dot blot assay. Samples were measured after ThT experiments with 5 









































































them exhibited very interesting and distinct fiber morphologies, which could be of interest for 
further investigation, as some of them have been reported to be amyloid inhibitors in the absence 
of membrane. Some of them appeared to produce fibers that were unbranched and highly uniform 
(AQ-1, AQ-2, AQ-7, and BD-1) Other showed less ordered morphologies, with attributes such as 
branching or amorphous aggregates attached to the outside of the fibers (THQ-1, AQ-3, BD-2, and 
BF-2). Investigations into these structures may prove fruitful in understanding both the binding 
selectivity’s of ThT and the OC antibody, since these 9 compounds have generated fiber structures 
that are invisible to both of these techniques.  
Understanding the secondary structure transitions is important for amyloid investigation, 
as there is a known shift from a random-coil monomer to β-sheet fiber. To study the compounds’ 
effects on Aβ secondary structure, the 5 non-water-soluble compounds were incorporated in the 
lipid bilayer, which was confirmed by UV-Vis (Figure B.5). Upon incorporation of the compounds 
in the LUVs at a 10:1 lipid to compound molar ratio, we monitored the Aβ structural transitions 
by circular dichroism (CD) experiments as well as by ThT kinetics (Figures 3.5 and B.6). After 22 
hours, AQ-4 and BF-3 still exhibited a random-coil structure. DHQ-2 and THQ-1 showed a minor 
 
Figure 3.5. CD spectra of 25 μM Aβ40 in the presence of 500 μM of compound loaded LUVs 
from 0 hours – 7 days. 
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helical conformation, while DHQ-1 showed a strong β-sheet conformation for Aβ. Up to 7 days, 
AQ-4 maintained random-coil conformation, whereas BF-3, DHQ-1, and DHQ-2 showed β-sheet 
conformation. THQ-1, however, showed poor signal and showed some slight β-sheet 
characteristics for Aβ was not fully interpretable at 48 hours, but appeared more clearly β-sheet 
after 7 days. 
Using NMR, we investigated the interaction of Aβ40 with the 5 compounds both with and 
without the presence of loaded LUVs using SOFAST-HMQC experiments (Figures 3.6 and B.7). 
This experiment is useful in determining the level of peptide aggregation (or monomer depletion) 
in solution. Because large aggregates such as amyloid fibers tumble slowly on the NMR timescale, 
they do not contribute to the observed signal and any signal is conferred to be fast tumbling 
oligomers or monomers. The signal to noise ratios, volume and line width of each peak as were 
analyzed (Figures 3.6 and B.7). In the presence of LUVs, Aβ40 showed 21 well-resolved peaks at 
time zero. After 24 hours, many of the peaks remained visible, but with decreased signal to noise 
intensities, indicating a depletion of monomers in solution via aggregation or binding to LUVs. 
Many of the peaks also broadened at 24 hours, another sign of aggregation. At 96 hours, almost 
all peaks had become invisible on the spectra and with very poor signal to noise ratio. For all 5 
compound samples, NMR spectra showed the same Aβ40 peaks as the control, however THQ-1 
exhibited poor S/N. After 24 hours a decrease in the S/N ratio can be seen for all 5 samples, but 
notably THQ-1 had no detectable signals remaining. After 96 hours, DHQ-1 DHQ-2 and AQ-4 
still maintained good signal to noise ratio in comparison to the 0 hour and 24-hour time point. The 
BF-3 S/N continued to decrease at 96 hours indicating the Aβ40 in this sample either aggregated 
the most in comparison or had the greatest amount that bound to the LUVs and no longer was 
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tumbling freely. AQ-4 showed a significant increase in linewidth after at 24 and 96 hours in 
comparison to the control. BF-3 also showed an increase in linewidth at 24 hours, but then 
decreased below the control after 96 hours. DHQ-1 and DH-2 showed minor changes in linewidth 
but overall maintained the same linewidths at all timepoints.  It is also probable that some of the 
signal loss and changed in linewidth could be due to the binding of Aβ40 to the 100 nm LUVs. This 
binding could cause the loss in signal intensity due to the decreased tumbling rate of the very large 
 
 
Figure 3.6. (Top) SOFAST-HMQC NMR spectra of 25 μM 15N- Aβ40 in the presence of 500 μM 
of compound loaded LUVs at 0 (black), 24 (red) and 96 hours (green). (Bottom) Signal to noise 
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LUV. Investigations utilizing smaller membrane mimetics such as nanodiscs and implementing 
paramagnetic quenching could be an enlightening next step to understand these systems.  
Experiments in the absence of LUVs were also performed in order to investigate the 
compound interactions on Aβ40 itself (Figures B.8-B.10). After 96 hours the control sample of Aβ40 
alone the S/N ratio was very poor, and only residue V39 was visible via linewidth and peak 
volume. The sample with THQ-1, well resolved peaks of Aβ40 were seen at all time points, opposite 
of what was seen with lipids. This indicates that THQ-1 interacts and inhibits Aβ40 aggregation 
but does not interact well in the presence of lipids, at least when loaded with lipids, since it 
appeared to be a strong inhibitor in the assays prior to loading the compounds in LUVs. Samples 
of Aβ40 with AQ-4, DHQ-1 and DHQ-2 all showed decreased S/N ratio and peak volume after 96 
hours in comparison to the samples with LUVs.  The Aβ40 sample with BF-3 remained comparable 
to the sample with LUVs in S/N ratio and peak volume. All 5 sample with compounds showed 
increases in linewidths for all 5 samples after 96 hours, indicative of slower to tumbling of these 
residues due to binding via protein-protein interactions or the protein ligand interactions. 
After the NMR measurements, the samples in presence of lipids were analyzed using Size 
Exclusion Chromatography (SEC) (Figures 3.7 and B.11). Three distinct peak areas were seen and 
the area under each curve was quantified to determine the distribution of aggregates within the 
 
Figure 3.7. (Top) Size exclusion chromatography of Aβ40 NMR samples in the presence of 





sample. Peak area 1 (between 5 and 8 mL) consisted of multiple peaks most likely made up of 
LUVs and Aβ40 amyloid fibers. Peak area 2 (15 mL) most possibly corresponds to an oligomer of 
4 monomers (~17 kDa) or an oligomer of 3 monomers with each bound to 2 compounds (~16 
kDa). Lastly, Peak area 3 could correspond to monomer and dimer of Aβ40, eluting at 21.5 and 20 
mL respectively.  Since, these samples contain lipids, it is possible that a portion of the intensity 
of the peaks is also lipids that have been fragmented from the LUVs. For AQ-4, DHQ-1 and BF-
3, over 50% of the eluted sample was either in peak area 2 or 3, indicating the presence of a small 
amount of fibers. While the control, THQ-1, and DHQ-2 samples had 60% or more of the total 
signal in peak area 1. The control samples showed no signal inside of peak area 2. Additionally, 
there was a very small peak seen at 11 mL which could indicate a very large oligomer or 
protofibers. Inside peak area 1, three distinct peaks were observed: one for LUVs at 7.5 mL, one 
for fibers at 6.5 mL, and in between them; there is also a less resolved peak that may be Aβ40 bound 
to LUVs, which is also not well resolved with the control sample of Aβ40 in LUVs. For the control 
LUVs sample, a small percentage of the total sample eluted in peak area 3, which could correspond 
to small lipid micelles. This could indicate that some of the signal in the other samples may also 
 
Figure 3.8 Dye leakage experiments using compound loaded LUVs filled with 6-
carboxyfluorscin. Dye leakage was measured in 20 mM phosphate 50 mM NaCl buffer at 37 °C 
with slow shaking over 40 hours. Percentage of dye released was determined after LUV lysis 
with triton-X. 
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contain micelles or lipids that have been fragmented from the bilayer as the result of the peptide 
aggregation on the membrane.  
Since A40 has been shown to cause pore formation and fragmentation of the lipid bilayer 
it is useful to know if the compounds change this proposed mechanism of toxicity. To investigate 
how the incorporation of the compounds changes the interactions with the lipid bilayer, we 
performed a dye leakage assay using lipid vesicles loaded with the 5 compounds filled with 6-
carboxyfluroescien (Figure 3.8). As previously seen, Aβ40 caused significant dye leakage (50%) 
of vesicles composed of 7:3 DOPC:DOPG lipids, indicating that the peptide is disrupting the lipid 
bilayer during its aggregation. It is interesting to note that the lag time of the dye leakage is longer 
than that of the ThT assays of the loaded vesicles (Figure B.6). This extended lag time may indicate 
and importance of the fiber mediated fragmentation of the vesicles. Loaded vesicles with the 5 
compounds all caused less dye leakage than the control. DHQ-1, DHQ-2 and THQ-1 all showed 
final dye leakage intensities around 15%, indicating a partial blockage of membrane disruption by 
Aβ40.  AQ-4 showed very little dye leakage, while BF-3 showed the most. BF-3 loaded vesicles 
final dye leakage intensity was almost 30% double the dye leakage of the other inhibitors. The lag 
time of the dye leakage is also extended in comparison to the control in which the control is ~5 
hours and the BF-3 vesicles are ~15 hours. These finding are quite fascinating when in conjunction 
with all the other biophysical data.   
3.3 Conclusion  
A high-throughput screen has led to the identification of 5 membrane active Aβ40 amyloid 
inhibitors, with a brief summary in Table 1. Among them, DHQ-1, DHQ-2 and THQ-1 were found 
to be the least robust as shown by NMR, SEC and CD results, whereas BF-3 and AQ-4 exhibited 
the most evidence that they are able to stop the aggregation (or trap the aggregates) at the 
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membrane interface. AQ-4 showed the highest ratio of oligomers by SEC, a constant random-coil 
signal from CD as well as maintaining good signal intensity in samples with and without 
membrane. This could indicate that even though AQ-4 interacts with the membrane, it is also able 
to directly interact with Aβ40.. AQ-4 also showed the least amount of dye leakage. Perhaps this is 
due to the fact that it seems to maintain its random coil structure and it could be possible that while 
it is interacting with the membrane surface, it is superficially interacting and not able to penetrate 
the bilayer because of its secondary structure. BF-3 also had interesting results. It showed no 
aggregation by ThT, appeared beta-sheet by CD, and maintained NMR signal but saw an overall 
loss in intensity in every residue and showed smaller species by SEC. These observations could 
indicate that while BF-3 does not allow Aβ40 to aggregate, some Aβ40 population is still binding 
to the membrane surface. BF-3 particularly showed the most amount of dye leakage and taking 
this into consideration with the loss of signal intensity via NMR experiments would indicate that 
it is binding to the membrane and casing pore formation. While DHQ-1 DHQ-2 and THQ-1 are 
less membrane active, they are still novel scaffolds for the inhibition of Aβ40. Although DHQ-1 
and DHQ-2 showed some differences in activity, they may be a good starting point for developing 
derivatives. Given their similar architecture and sites for potential for synthesis, they could be used 
in an interesting study for structure activity relationship (SAR) analysis. The initial investigation 
and subsequent rule out of THQ-1 demonstrates the need for deep characterization for amyloid 
and small molecule interactions.  
Given AQ-4 and BF-3 parallels in membrane activity, it is possible that this may be due to 
their planar structure and lack of free rotation among the aromatic groups. However, many 
compounds initially investigated as part of the 21 primary hits also had this feature but produced 
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prominent fibers, so clearly there must be unique properties possessed by these two compounds 
and their interplay between Aβ40 and the membrane which render their inhibitory activity. With 
the presented data as a starting point, NMR would be a robust tool to investigate the structure of 
the Aβ40 in the presence of compounds as well as in conjunction with the membrane.    
 
3.5 Materials and Methods 
3.5.1 Screening Protocol 
A library of 1,800 compounds were selected from Pilot Prestwick, Navigator Pathways and 
Maybridge libraries from the Center of Chemical Genomics (CCG) from the University of 
Michigan High Throughput Screening core facility. Thioflavin-T was selected as the primary read 
out for the screen and was used at 20 μM final concentration. All reagents were kept on ice until 
 
 





dispensing onto the plate. The screening was performed using Aβ40 expressed in E.coli and purified 
as described elsewhere23 and was used at a final concentration of 10 μM. Large unilamellar vesicles 
(LUVs) of  a 7:3 mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-
sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG) were prepared from chloroform stocks and made 
into lipid films by evaporating chloroform under nitrogen gas and then by lyophilization. Films 
were then rehydrated into buffer and then extruded to a size of 100 nm and were used at a final 
concentration of 500 μM. lipids and extruder were purchased from Avanti polar lipids. A buffer 
of 20 mM Phosphate 50 mM NaCl at pH 7.4 was used in all experiments. The assay was performed 
in 384 polystyrene plates from corning (product number 3640) with a non-binding surface. Each 
well was equipped with a single 0.5 mm sterile glass bead that will be added using a custom made 
bead dispenser from LabTIE, in order to act as a miniature stir rod to overcome the surface tension 
to ensure sufficient mixing during shaking.24 Buffer was initially loaded into plates at a volume of 
15 μL before adding the compounds dissolved in DMSO at a final concentration of 100 μM using  
a Biomek FX liquid handling automatic workstation.  The remaining buffer, ThT, LUVs and Aβ40 
were added using Plates Thermo Fischer Mutli Drop Combi to a final volume of 30 μL and then 
sealed. Initial fluoresce readings were done from each plate at 440ex/480em using a Perkin Elmer 
2014 Envision Multilabel plate reader on bottom read setting. After the initial reading, plates were 
moved to a mutilplate shaker kept inside an incubator set at 37 °C and were shaken for 24 hours 
at 750 rpm. After 24 hours of heating and shaking the plates fluorescence intensity was measured 
again. Each compound was added to duplicate plates in order to rule out false positives and to 
overcome the reproducibility issues among wells often seen with amyloid aggregation assays. 
After initial hits were identified, the top 40 hits were validated via the same protocol as described; 
however the compounds were titrated at 8 concentrations between 2-100 μM using TTP Labtech’s 
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Mosquito nanolitre hit picking system. From the concentration response curves (CRC) 21 
compounds were selected based on the generated IC50 values and as well as removing compounds 
known to be PAINS. After the 21 compounds were selected, fresh compounds were bought from 
manufactures as shown in TableB.1 and dissolved in DMSO. Full kinetic ThT profiles were 
obtained for each compound at 100, 50 and 20 μM concentrations. Reagents were prepared in the 
same manner as done in the screen but with using multichannel pipettes in place of robotic 
handling. Samples were plated in quadruplicates on 384 well plates, maintained at 37 °C and 
subject to continuous, slow orbital shaking. Fluorescence readings were taken on a Biotek Synergy 
2 microplate reader and were read from the bottom with an excitation wavelength of 440 nm (30 
nm bandwidth) and an emission wavelength of 485 nm (20 nm bandwidth) at three-minute 
intervals.  
3.5.2 Dot Blot Assay 
2 μL from the 50 μM compound containing ThT assay wells were spotted onto the nitrocellulose 
membrane in duplicate. Wells containing only compound and the LUVs were also spotted for 
control. Non-specific binding sites were blocked by soaking in 5% BSA in TBS-T for 30 min at 
RT. The primary Anti-Amyloid Fibrils OC Antibody at a 1:2000 dilution in 5% BSA in TBS-T 
for 30 min at RT. The membrane was washed with TBS-T (3 x 5 min). Rabbit secondary antibody 
at a 1:1000 dilution was incubated for 30 min at RT. The membrane was washed with TBS-T (1 x 
15 min and 2 x 5 min), and then incubated with ECL reagent for 1 min and sealed. Immediately 
after ECL reagent incubation, membranes were exposed using X-ray film in a dark room for 30 
seconds. Images and intensities of spots were processed using ImageJ software. 
3.5.3 Transmission Electron Microscopy 
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Samples used in TEM analysis were taken directly from ThT experiments on the wells of 5 
equivalents of compound after 24h incubation. Glow discharged grids (Formar/carbon 200 mesh, 
Electron Microscopy Sciences, Hatfield, PA, U.S.A.) were treated with samples (7 µL) for 2 min 
at room temperature. Excess buffer was removed via blotting and then washed three times with 
ddH2O. Each grid was then incubated with uranyl acetate staining solution (1% w/v in ddH2O, 7 
µL) for 1 min, and excess stain was blotted away. Images from each sample were taken on a JEOL 
1400-plus TEM (80 kV) at varying magnifications.  
3.5.4 Small molecule incorporation into lipids 
The 5 compounds were dissolved into chloroform stocks and then added to lipid mixtures in 
chloroform at a 10:1 lipid to compound molar ratio. The lipid films were made as described above 
for final concentrations of 50 μM compound within 500 μM lipids. Compounds containing LUVs 
were extruded and then checked for incorporation using UV-Vis measurements. Extruded 
solutions appeared clear and maintained clarity for up to 7 days on the bench top. 
3.5.5 Circular Dichroism 
Single point CD measurements were carried out at 25 µM Aβ40 concentration in the presence of 
500 μM lipids loaded with 50 μM of compound. CD measurements were performed on a JASCO 
J- 1500 CD Spectrometer using a 0.1 cm path-length cell. Spectra were acquired at 25 °C using a 
bandwidth of 2 nm, a scan rate of 200 nm/min, and averaging spectra over 10 scans with a 
smoothing factor of 13. Measurements were taken immediately after mixing the sample (t = 0 h) 
and after various time points.  
3.5.6 NMR experiments 
2D 1H/15N SOFAST-HMQC NMR spectra were recorded on a Bruker 800 MHz NMR 
spectrometer equipped with a 5mm triple resonance inverse detection TCI 
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cryoprobe. NMR samples were prepared in 20 mM phosphate, 50 mM 
NaCl  buffer (pH 7.4) containing 10% D2O at  298.2 K. Freshly dissolved 15N-labeled Aβ40 was 
mixed with liposomes containing 500 μM of lipids and 50 μM of incorporated compound, as well 
as in the absence of lipids with the compounds dissolved in deuterated DMSO at 50 μM.  All 
NMR samples were stored at 37 °C during the time-lapse measurements. Each NMR spectrum 
was obtained using 256 t1 increments, 16 scans, 16 dummy scans and a recycle delay of 0.2 
s. NMR data were processed using TopSpin 3.5 (Bruker) and analyzed using Sparky 3.114.  
3.5.7 Size exclusion chromatography 
NMR samples were used for SEC characterization. 200 µL of each sample was loaded using 
Superdex 75 Increase LS Tricorn 10/300 column operated on an AKTA purifier (GE Healthcare, 
Freiburg, Germany) read at 214 nm with a flow rate of 1mL/min. 
3.5.8 Dye Leakage assay 
Lipids and the 5 small molecules in chloroform were placed in vials at the desired ratios and 
solvent was evaporated with N2 gas. Films were hydrated with 50 mM 6-carboxyfluorescein dye 
and put through no less than five freeze-thaw cycles. Following this, these samples were extruded 
through a 100 nm pore membrane no less than 21 times and filtered through a disposable PD-10 
desalting column to separate dye filled vesicles from free 6-carboxyfluorescein in solution. The 
first 3.5 mL of elutant from the column were discarded and the following 1.5 mL of elutant of dye 
filled vesicles was collected. DLS was checked for to ensure 100 nm LUVs present in fractions. 
LUVs were diluted into buffer and then used for dye leakage assays on a 96 well plate in 20 mM 
phosphate 50 mM NaCl buffer at 37 °C with slow shaking over 40 hours in the presence of freshly 
prepared 10 μM Aβ40  Percentage of dye released was determined after LUV lysis with triton-X 
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Conclusions and Perspectives 
4.1 General Conclusions 
 The complexities of amyloid diseases make them a difficult target for treatment 
development.1–4 The variations in the aggregation pathway contribute to the lack of understanding 
which singular components are the root cause.5–9 Many years of research, for AD in particular, has 
been spent investigating treatments of various types to treat these diseases, but the research has 
fallen short and no treatments to treat the underlying cause has been FDA approved.10–17 While 
high resolution structures exist for the monomers and fibers of most amyloid diseases, it is the 
various states in the aggregation pathway that remain out of reach. Development of tools to isolate 
these species so that they can be fully characterized can lead to a deeper understanding of their 
nature, either toxic or not. Through a combination of biophysical techniques, we have 
characterized and identified tool compounds that are able to study intermediates.  
 Chapter 2 focuses on the selectivity of CurDAc, a water-soluble curcumin derivative on its 
peptide selectivity and its ability disaggregate to hIAPP as well as prevent aggregation. It was 
observed that CurDAc was a more potent inhibitor and disaggregator of hIAPP over hCT and Aβ40 
by carrying out biophysical experiments including the ThT assay, CD, TEM and ITC experiments. 
Additionally, utilizing single and multidimensional NMR experiments we were able to 
characterize both the monomer based inhiation of hIAPP aggregation as well as the disaggregation 




However, the peptide does not remain visible for NMR experiments indicating an increase in the 
size of the aggregate. The disaggregated species was structurally distinct from the monomer 
according to NMR. The peak positions of the disaggregated species identified from 2D and 3D 
NMR experiments have distinct chemical shifts in comparison to the monomer but do not 
necessarily match known chemical shift values based on secondary structure for those particular 
amino acids. However, most of the residues identified in the disaggregated species exist in a loop 
region of the monomer and fiber models, as well as a membrane bound intermediate of hIAPP. 
This evidence suggests that these residues are incorporated into a larger oligomeric species that is 
too large for solution NMR studies, while the identified residues are solvent exposed.  TEM 
confirmed the disaggregation of fibers to smaller aggregates. Importantly, it was identified that 
both the CurDAc inhibited and disaggregated hIAPP were toxic to cultured cells, indicating the 
isolation of toxic intermediate using a small molecule tool. 
 Chapter 3 continued on the idea of small molecule tools to isolate amyloid intermediates. 
However, this work focused on the importance of membrane as a site for amyloid toxicity, which 
is important for AD. Generation of Aβ occurs in the plasma membrane and it has been shown to 
bind to and disrupt membranes as well as bind to membrane bound receptors.18–28 Given the 
importance of membranes, we set out to identify small molecules that could act aggregation 
inhibitors and tool compounds in the presence of a membrane, since most Aβ inhibitors do not 
function with membranes. A high throughput screen of 1,800 small molecules revealed 5 
membrane-active Aβ40 inhibitors were found, none of which had been investigated for amyloid 
inhibition before. Although there were 5 inhibitors identified, they differed in their activity. Of the 
compounds, DHQ-1, DHQ-2, and THQ-1 were found to be the least inhibiting by NMR, SEC and 




smaller species by SEC, maintained a random coil CD signal and visible C terminus by NMR. BF-
3 also showed a large amount of smaller species and had NMR peaks visible throughout the whole 
sequence but appeared beta sheet by CD. Interestingly, BF-3 allowed dye leakage from membranes 
with in without GM1 indicating that Aβ40 is disrupting the bilayer however AQ-4 did not.  
4.2 Future Outlook 
 The work presented in this dissertation have created an avenue for the development of tool 
compounds to manipulate amyloid aggregation. Given the many complexities of amyloid diseases 
and lack of treatments, it is crucial that research at a variety of angles continues forward. This work 
has provided a starting point for possible derivatization of small molecule tools for amyloid 
modulation for the purposes of disaggregation, promotion and inhibition at the membrane. 
Similarities among identified inhibitor compounds provide a starting point for structure activity 
relationships to be drawn. Compounds that didn’t inhibit in the presence of a membrane could also 
be investigated for this purpose.  
While the research presented here has provided new insights into amyloid disaggregation 
and inhibition, atomic level resolution structures were out of reach. While preliminary structural 
data in chapters 2 and 3 were presented, further structural biology works are needed to achieve the 
highest level of atomic level resolution of the intermediates. Stabilizing and isolating amyloid 
intermediates would enable atomic-resolution dynamic-structural studies using a combination of 
solution and solid-state NMR techniques. While solution NMR can be applied to monitor the 
formation of small molecular weight oligomeric intermediates, large size aggregates, protofibers 
and fibers can be investigated using well-established solid-state NMR techniques. Isolation and 
purification of the intermediates would be suitable for solid state NMR experiments.29 Current 




solving a number of fiber structures.30–35 With advancements in resolution and class averaging, it 
is possible that large oligomer structures may be solved with Cryo-EM. 36,37 Recent successful 
developments of near-native membrane mimetics, such as lipid-nanodiscs, would be a next step 
for the evolution of the work shown in chapter 3. Recently, nanodiscs were used to trap an oligomer 
of hIAPP , used in biophysical characterization including high-resolution NMR experiments and 
molecular dynamics simulations to generate the first high-resolution structural model.38 The use 
of the nanodiscs could be an avenue to pursue for the investigating the structures of the small 
molecules and Aβ40 interactions at the membrane interface.  
 While much work continues to emerge in the amyloid field, a lack of answers has caused 
a reflection on the ‘amyloid hypothesis'. 14,39,40 This may be because the ‘toxic oligomer” still 
remains a structural mystery and the transient and ever evolving nature of them makes it quite 
difficult to apply the existing biophysical and biochemical techniques available to fully 
characterize them. With new methods to isolate the intermediate species presented here, hopefully 
amyloid research will move forward in providing answers to patients and loved ones affected with 
these diseases.  
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Figure A.2 Amino acid sequences of the three different amyloid peptides (amyloid-beta, human-
IAPP and human-calcitonin) used in this study. Color indicates charge of residue at pH 7.4: red is 











Figure A.3 Kinetic disaggregation curves using 4 equivalents of ThT. 10 μM peptides (hIAPP, 
hCT and Aβ) were allowed to aggregate to form amyloid fibers, as shown in the black curve in 
each figure, with 40 μM ThT to monitor aggregation. Wells were then treated with the same 






















































































Figure A.4  Isothermal titration calorimetry (ITC) experimental traces showing the monomer and 
binding with CurDAc over time. hIAPP monomer and Aβ fiber show no thermodynamic binding. 





























Figure A.5 NMR aggregation kinetics of hIAPP and hIAPP + CurDAc as measured by 1D 1H 
signal intensity. 100 μM hIAPP dissolved into pH 7.4 phosphate or pH 5.3 acetate buffers with 
and without CurDAc were used to measure the proton NMR spectra of the soluble hIAPP peptide. 
Experimentally measured proton NMR signal intensities are plotted over the time. First spectra 
were taken immediately after addition of CurDAc to hIAPP monomer and subsequent spectra were 
taken at various time points. 
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Figure A.6 1H NMR spectra of hIAPP monomer with 1 equivalent of CurDAc over time obtained 
from a 850 MHz NMR spectrometer at 25 °C. Red trace spectrum shows 80 μM hIAPP + CurDAc 
at pH 5.3 acetate buffer at 0 hours. Blue trace spectrum shows the same sample after 9 hours of 

























Figure A.7 Secondary structure predictions of hIAPP monomer in the presence of CurDAc using 
the Ca, Cb, HN  and N chemical shifts. (A) Secondary structure propensities from the Forman Kay 
group. (B) Random Coil Index from the Wishart group and (C) the Δδ of the Ca chemical shifts. 
All three show a tendency of an alpha-helical structure at the N-terminus, a small portion of a beta-
sheet confirmation near the amyloidogenic core, and then a random coil for the rest of the peptide, 
which is closely similar to the hIAPP monomer structure. 
 
 




























































Figure A.8 3D HNCA and HNCOCA experiments performed after 72-hour incubation of hIAPP 
with CurDAc at a 1:1 molar ratio at pH 7.4 phosphate buffer obtained from a 850 MHz NMR 










Figure A.9 Circular dichroism (CD) and TEM of hIAPP fibers before and after CurDAc treatment. 
(A) CD spectra of hIAPP fibers in the presence of one molar equivalent of CurDAc over a course 
of 60 hours in phosphate buffer at pH 7.4. TEM images of hIAPP fibers (B) followed by hIAPP 
samples in the presence of CurDAc at 30 minutes to 60 hours (C-F) scale bar is 200 nm. Full 






































Figure A.10 CD spectra of hCT and Aβ before and after treatment with CurDAc. 40 μM peptide 
monomers in pH 7.4 phosphate buffer show random coil at time zero, and after 24 hours peptides 
show beta-sheet conformation. hCT was treated with 2 equivalents of CurDAc, and Aβ with 10 
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Figure A.11 hCT and Aβ TEM images before and after treatment with CurDAc. Top, 40 μM hCT 
(left) and Aβ (right) after 24 hours shaking at pH 7.4 phosphate buffer at 25°C and 37°C. Bottom, 
30 minutes after the addition of CurDAc. 2 equivalents of CurDAc were added to hCT and 10 






























Figure A.12 MTT cell toxicity assay of curcumin and CurDAc. RIN-5F cells treated with 








































































Figure A.13 RIN-5F cell death monitored every 10 minutes for 13 hours by CellTox Green 
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Table A.1 hIAPP fiber and CurDAc parameters as determined from isothermal titration 
calorimetry (ITC) data (Figure A.4). Dissociation constant (Kd), DHbind and n value were obtained 
by fitting with one site binding model. DGbind was calculated based on the relation of DGbind = –















hIAPP Fibers + CurDAc 
DGbind (kcal mol-1) -7.3 
DHbind (kcal mol-1) -9.9 
-TDSbind (kcal mol-1) 2.6 
Kd (μM) 6.8 









3 ASN 39.086 52.678 124.2993 8.7713 
4 THR 70.7557 61.1146 110.6628 7.3559 
5 ALA 18.1791 54.5815 122.7183 8.5197 
6 THR 69.2207 62.9297 109.5424 7.7255 
7 CYS 40.8762 56.1385 120.4087 7.8619 
8 ALA 18.5302 53.6451 124.1765 7.9618 
9 THR 69.2217 63.1576 113.7145 7.9175 
10 GLN 28.6872 56.2058 122.5101 7.995 
11 ARG 30.3224 56.6439 107.936 8.0404 
12 LEU 41.949 55.3473 122.5421 7.8186 
13 ALA 18.7643 53.0598 123.6314 7.959 
14 ASN 38.3345 53.3773 116.6722 7.9961 
15 PHE 38.7921 58.0063 120.0362 7.793 
16 LEU 41.8671 55.4569 122.3817 7.9103 
17 VAL 32.3546 62.3499 120.7697 7.7196 
18 HIS 28.8801 55.1115 122.0749 8.3102 
19 SER 63.6187 57.9878 117.5163 8.1642 
20 SER 63.5594 58.1272 117.7381 8.2202 
21 ASN 38.512 53.0921 120.0117 8.1941 
22 ASN 38.33 53.0878 118.6576 8.0778 
23 PHE 38.6758 53.2115 120.383 8.0217 
24 GLY 
 
45.0546 110.1381 8.093 
25 ALA 19.0472 52.1137 123.4318 7.7682 
26 ILE 38.3073 53.4572 120.4079 7.9671 
27 LEU 42.0765 55.069 127.034 8.21 
28 SER 63.6187 57.9614 117.0866 8.1641 
29 SER 63.589 58.1391 117.6773 8.2614 
30 THR 69.4109 61.8517 115.0143 7.9413 
31 ASN 38.4558 53.1274 121.2654 8.1871 
32 VAL 32.3427 62.4194 120.7386 7.9667 
33 GLY 
 
45.1069 112.3688 8.3088 
34 SER 63.5668 58.0292 115.4101 8.0113 
35 ASN 38.4711 53.1296 120.5407 8.3178 
36 THR 69.4109 62.0605 114.2089 7.8543 
37 TYR 38.4335 57.7016 122.6677 7.9345 
Table A.2 Chemical shifts from 3D HNCA, HNCOCA experiments of CurDAc interactions with 








Table A.3 Parameters obtained by fitting circular dichroism spectra of hIAPP time course 
disaggregation with CurDAc using BeStSEL. Values are shown in percentage of total content. 
 
















Fiber 0 0 0 7.1 7.46 19.93 9.32 10.23 54.04 45.97 0.0215 
30 Minutes 9.14 0 9.14 0 0 19.46 20.12 8.66 48.24 42.63 0.0334 
16 Hours 10.49 1.83 12.32 0 0 16.6 19.67 7.48 43.75 43.93 0.0366 
40 Hours 0 2.69 2.69 0 0 14.23 23.63 13.73 51.59 45.72 0.0529 




Table A.4 Statistical significance calculated by one-way ANOVA using Tukey’s multiple 




Samples Compared Significant? Summary Adjusted P Value 
hIAPP monomer MTT Experiments 
5  μM vs. 5  μM + 1 equiv. CurDAc Yes **** <0.0001 
1  μM vs. 1  μM + 1 equiv. CurDAc Yes **** <0.0001 
0.5  μM vs. 0.5  μM + 1 equiv. CurDAc Yes **** <0.0001 
5  μM + 1 equiv. CurDAc vs. 1  μM + 1 equiv. CurDAc Yes ** 0.0034 
5  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc Yes **** <0.0001 
1  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc No ns 0.0855 
hIAPP Fiber MTT Experiments 
5  μM vs. 5  μM + 1 equiv. CurDAc No ns 0.9985 
1  μM vs. 1  μM + 1 equiv. CurDAc Yes **** <0.0001 
0.5  μM vs. 0.5  μM + 1 equiv. CurDAc Yes **** <0.0001 
5  μM + 1 equiv. CurDAc vs. 1  μM + 1 equiv. CurDAc Yes **** <0.0001 
5  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc Yes **** <0.0001 
1  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc No ns 0.1464 
hIAPP Monomer  CellTox Green Experiments     
5  μM vs. 5  μM + 1 equiv. CurDAc Yes **** <0.0001 
1  μM vs. 1  μM + 1 equiv. CurDAc No ns 0.5995 
0.5  μM vs. 0.5  μM + 1 equiv. CurDAc No ns 0.9128 
5  μM + 1 equiv. CurDAc vs. 1  μM + 1 equiv. CurDAc Yes *** 0.0002 
5  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc Yes *** 0.0003 
1  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc No ns 0.9998 
hIAPP Fiber CellTox Green Experiments 
5  μM vs. 5  μM + 1 equiv. CurDAc Yes **** <0.0001 
1  μM vs. 1  μM + 1 equiv. CurDAc No ns 0.5284 
0.5  μM vs. 0.5  μM + 1 equiv. CurDAc No ns 0.7522 
5  μM + 1 equiv. CurDAc vs. 1  μM + 1 equiv. CurDAc Yes **** <0.0001 
5  μM + 1 equiv. CurDAc vs. 0.5  μM + 1 equiv. CurDAc Yes *** 0.0001 
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Figure B.1. Representative data of final ThT fluorescence intensity of a 384 well plate from 
the screen. Columns 1 and 2 were negative controls and columns 23 and 24 were positive 
controls. Each individual well had a unique compound outside of the controls. Wells with 





Figure B.2. Concentration response curves for the 21 compounds selected further investigation. 





























































































































































































































































































































































































































































































































































































































































Figure B.3. Concentration response curves for compounds not selected for further testing. 

























































































































































































































































































































































































































































































































































































Figure B.4. Dot blot images of samples after the ThT experiments using the OC antibody. 

















Figure B.5. UV-Vis spectra of AQ-4, THQ-1, BF3-, DHQ-1, and DHQ-2 in DMSO (black) and 
incorporated into LUVs after extrusion (red). Molar ratio of lipids to compound was 10:1. 
 















AQ-4 LUV after extrusion















THQ-1 LUV after extrusion















DHQ-2 LUV after extrusion















DHQ-1 LUV after extrusion






























Figure B.6. ThT fluorescence kinetics of 10 μM Aβ40 (black) and Aβ40 + 500 μM of 

































































































































Figure B.7.  (Top) Peak volumes taken from SOFAST-HMQC NMR spectra of 25 μM 15N- Aβ40 
in the presence of 500 μM of compound loaded LUVs at 0 (black), 24 (red) and 96 hours (green). 
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Figure B.8. ThT fluorescence kinetics for 10 μM Aβ40 (black) and varying equivalents of 





























































































































Figure B.9.  SOFAST-HMQC NMR spectra of 25 μM 15N- Aβ40 in the presence of 50 μM 








Figure B.10. (Top) Peak volumes taken from SOFAST-HMQC NMR spectra of 25 μM 15N- Aβ40 
in the presence of 50 μM compound at 0 (black), 24 (red) and 96 hours (green). (Middle) S/N 
ratios taken from spectra at 0, 24 and 96 hours. (Bottom) Linewidths taken from spectra at 0, 24 
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Figure B.11. SEC profiles of 100 nm LUVs loaded with small molecules at a 10:1 lipid:compound 
molar ratio. 

















































































B.1 Supplementary Tables 
 
Table B.1. Information on the 21 primary hits selected form the screen.  
 
CCG Code Average IC50 Name (IUPAC or Common) Supplier 
CCG-208404 15 Maritimein Carbosynth 
CCG-49784 5.4 
1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-
1,2,3,4-tetrahydroisoquinoline hydrochloride Sigma Aldrich 
CCG-208399 2.86 Shikonin beta Sigma Aldrich 




CCG-220101 9.2 Apomorphine hydrochloride hemihydrate  Sigma Aldrich 
CCG-208272 9.114 Shikonin Sigma Aldrich 
CCG-208289 18.7 Wedelolactone Molport 
CCG-208275 22.6 Tanshinone IIA Sigma Aldrich 
CCG-220307 14.15 Oxytetracycline dihydrate Sigma Aldrich 
CCG-100627 20 Piceatannol Molport 
CCG-208582 21 Hypocrellin A Carbosynth 







CCG-39571 16 Levodopa Sigma Aldrich 
CCG-208268 4 Rosmarinic acid Sigma Aldrich 
CCG-208196 50 Doxorubicin Molport 
CCG-208189 13 Daunorubicin Molport 
CCG-35263 53 Emodin Sigma Aldrich 






Table B.2. Common name, given abbreviation, and structure of the 21 primary hits. 
 
 
